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Summary  
Influenza Virus (IV) activates the Raf/MEK/ERK-(MAPK) cascade late in their 
replication cycle. This is essential for efficient nuclear RNP-export and therefore for 
production of infectious IV. To characterize cellular factors involved in MAPK-
activation in the context of the viral infection I recently analyzed the role of PKC. The 
results so far indicate, that activation of the Ca
2+
 activated PKC is involved in the IV 
induced MAPK-signaling and that specific inhibition of this function using a Ca
2+
 
channel blocker (Verapamil) at non toxic concentration, negatively affects IV 
propagation (265). In addition, I have now further analyzed the action of Verapamil for 
possible additional negative effects on IV replication. Therefore I have investigated 
viral protein production in IV infected human lung epithelial cell line A549 and found 
that PB1, NP, and NS1 production is significantly reduced in IV infected and 
Verapamil treated A549 cells. Cell survival and cellular protein production does not 
seem to be affected ruling out a general effect of Verapamil on translation. Since PB1 is 
a functional important subunit of the viral polymerase the activity of the polymerase 
might be affected. Therefore I analyzed the polymerase activity in Verapamil treated 
cells for the production of viral mRNA using primer extension analysis of a reporter 
transcript expressed by either a plasmid based replication system or in virus infected 
cells.  
My current results show that viral mRNA production in the plasmid based replication 
system is not affected, while it seems to be reduced in virus infected cells. This 
indicates that Verapamil might alter viral transcription activity in virus infected cells. 
Taken together, PKC plays an important role in transmitting the influenza virus 
induced signal to the MAPK-cascade. As this PKC-inhibition can be achieved at non-
toxic Verapamil concentration, leading to strong reduction of virus titers, inhibition of 
this cellular activity might be a potential anti-viral therapy. 
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Hans-D. Klenk, Stephan Ludwig and Stephan Pleschka. “Membrane accumulation of 
influenza A virus hemagglutinin triggers nuclear export of the viral genome via PKC 
mediated activation of ERK signaling”. J. Biol. Chem., Vol. 281, Issue 24, 16707-
16715, April 2006. 
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Zusammenfassung 
Influenzaviren (IV) aktivieren die Raf/MEK/ERK (MAPK)-
Signaltransduktionskaskade in der späten Phase ihres Replikationszyklus. Dies ist 
essentiell für einen effizienten RNP-Kernexport und damit für die Produktion 
infektiöser Viren. Zur Charakterisierung zellulärer Faktoren, welche im Kontext der 
viralen Infektion die MAPK-Kaskade aktivieren, habe ich die Rolle von PKC 
analysiert. Die bisherigen Ergebnisse zeigen, daß die Aktivierung der Ca
2+
-aktivierten 
PKC an der virusinduzierten MAPK-Aktivität beteiligt ist, und das die Inhibition 
dieser Funktion durch einen Ca
2+
-Kanalblocker (Verapamil) in nicht toxischen 
Konzentrationen die IV-Vermehrung negativ beeinflußt (265). Zusätzlich habe ich 
weitere negative Effekte der Wirkung von Verapamil auf die IV-Vermehrung 
untersucht. Dafür habe ich die Produktion viraler Proteine in der IV-infizierten 
humanen Lungenalveolar-Epithelzellinie A549 analysiert. Dabei konnte ich zeigen, daß 
die Expression von PB1, NP und NS1 in infizierten und Verapamil-behandelten A549-
Zellen signifikant reduziert ist. Dabei führt die Verapamil-Behandlung nicht generell zu 
einer Beeinträchtigung des Zellüberlebens oder einer verringerten 
Zellproteinproduktion. Da PB1 eine funktionell wichtige Untereinheit der viralen RNA-
abhängigen RNA-Polymerase (RDRP) ist, könnte die RDRP beeinflußt sein. Deshalb 
untersuchte ich die Produktion viraler mRNA. Zum einen in transfizierten A549-Zellen 
in denen mittels eines plasmidgestützen Replikationssystem zur transienten Expression 
viraler RDRP und eines vRNA-ähnlichen Pol1-Transkriopts virale mRNA gebildet 
wurde. Zum anderen wurde in transfizierten Zellen nur das vRNA-ähnliche Pol1-
Trankript gebildet, welches dann durch die RDRP-Aktivität nach IV-Infektion der 
transfizierten Zellen repliziert und transkribiert wurde. Die jetzigen Ergebnisse der 
„Primer-Extension“-Analyse zeigen, daß die Produktion viralen mRNA in dem 
plasmidgestützten system nicht beeinflußt zu sein scheint, aber in den IV-infizierten 
Zellen. Das könnte bedeuten, daß Verapamil die virale Transkription in virusinfizierten 
Zellen beeinträchtigt. Zusammengefaßt kann man sagen, daß PKC eine wichtige Rolle 
in der Signaltransmission der IV-induzierten MAPK-Kaskade spielt. Da Verapamil in 
nicht toxischen Konzentrationen PKC inhibiert, die IV-Vermehrung hemmt und 
Verapamil als Pharmazeutika zugelassen ist, könnte Verapamil für einen anti-viralen 
therapeutischen Ansatz gegen IV nützlich sein. 
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1. Introduction 
1.1 The Causative Agent 
1.1.1 Influenza 
Influenza is caused by a virus that attacks mainly respiratory tract, the nose, throat, and 
bronchi and rarely also the lungs. The infection usually lasts for about a week. It is 
characterized by sudden onset of high fever, myalgia, headache and severe malaise, 
non-productive cough, sore throat and rhinitis. Most people recover within one to two 
weeks without requiring any medical treatment. In elderly people suffering from 
medical conditions, influenza poses a serious risk. In these people, the infection may 
lead to severe complications of underlying diseases, pneumonia and death. 
 
1.1.2 History of Influenza 
The origin of the name influenza is uncertain although the chronicles of a Florentine 
family used it in reference to the possible influence of the planets at times of respiratory 
epidemics (1). The Influenza is a distinctive disease and its comings and goings could 
not be predicted. The term influenza was used in England during the outbreak of 1743 
(2). Influenza has no pathognomic features, so a precise picture of its impact was 
impossible before the first isolation of influenza A virus in 1933 (3), influenza B virus 
in 1940 (4) and influenza C virus in 1947 (5). Influenza has been termed, ‘the last great 
plaque’ (6). Further knowledge of the illness came with the discovery of the 
hemagglutinating properties of influenza virus in 1941 (7) and development of 
diagnostic methods based on hemagglutination inhibition. However, in the absence of 
these tools, a combination of the explosive nature of influenza, its respiratory and 
systemic features, its tendency for seasonality, and its high attack rates and associated 
mortality in people of advanced age provides an insight into influenza since ancient 
times. 
 
1.1.3 Human influenza and transmission 
Influenza in man occurs in two epidemiological forms. The first is pandemic influenza 
which results from the emergence of a new influenza A virus - termed antigenic shift - 
to which the population possesses little or no immunity, it therefore normally spreads 
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with high attack rates throughout all parts of the world. The second is interpandemic 
influenza, occurring as a sporadic infections, a localized outbreak in a given community 
which usually occurs abruptly, peaks within 2-3 weeks, lasts 5-6 weeks, and is 
associated with significant ‘drift’ of the surface antigens. Influenza is spread by virus-
laden respiratory secretions from an infected to a susceptible person. The virus is easily 
passed from person to person through the air by droplets and small particles excreted 
when infected individuals cough or sneeze. The influenza virus enters the body through 
the nose or throat. It then takes between one and four days for the person to develop 
symptoms. Someone suffering from influenza can be infectious from the day before 
they develop symptoms until seven days after wards (WHO). 
The influenza pandemic of 1918-1919 killed more people than the Great War, at 
somewhere between 20-40 million people. It has been cited as most devastating 
epidemic in recorded world history. More people died of influenza in a single year than 
in four-years of the Bleck death Bubonic Plaque from 1347-1351. Known as “Spanish 
Flu” or “La Grippe” the influenza of 1918-1919 was a global disaster. 
 
 
 
The Influenza Pandemics of 1918 
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1.1.4 Clinical symptoms of influenza virus infection 
The replication of the virus leads to the lysis of the epithelial cells and enhanced mucus 
production causing running nose and cough. Furthermore, inflammation and oedema at 
the replication site are due to cytokines released. This can lead to fever and related 
symptoms. Bacterial super-infection of the harmed tissue can further complicate the 
situation. Normally onset of systemic (fever, myalgia, headaches, severe malaise) and 
respiratory (coughing, sore throat, rhinitis) symptoms occur after about two days 
incubation period and can last for about seven to ten days (186).  
 
1.1.5 Different types of influenza viruses 
Influenza viruses (IV) belong to the Orthomyxoviridae and are subdivided into three 
genera: type A, B and C (8), due to the characteristic of their nuclear and matrix 
protein. Currently circulating influenza viruses that cause human disease are divided 
into two group’s A- and B-type. Influenza A viruses (IAV) can infect humans, birds, 
pigs, horses, seals, whales and other animals (Figure 1.1.), whereas wild aquatic birds 
are the primary reservoir of these viruses (9). IAV has 2 subtypes, which are important 
for humans: H1N1 and H3N2, of which the former is currently associated with most 
deaths (WHO influenza health topic). IV are defined by 2 different protein components, 
known as antigens, on the surface of the virus. They are spike-like features called 
hemagglutinin (HA) and neuraminidase (NA) components. Type B influenza viruses 
are normally found only in humans. Although influenza B viruses can cause human 
epidemics, they have not caused pandemics. Type C infection usually causes either a 
very mild respiratory illness or no symptoms at all; it does not cause epidemics or 
pandemics and does not have the severe public health impact that influenza types A and 
B do. Unlike IAV, type B and C influenza viruses are not classified according to 
subtype. 
 
1.2 Influenza A virus 
1.2.1 Morphology and genome structure  
Influenza A viruses have been the most thoroughly investigated and are best understood 
genera among A, B and C. The structures of influenza A and B viruses are very similar 
although the B viruses are somewhat more irregular. 
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The virion of type A influenza virus is enwrapped by a lipid envelop derived from the 
plasma membrane of host cells (10) and has a fairly regular appearance in the electron 
microscope, with sizes that range from 80 to 120 nm in diameter (Figure 1.2.C) (11-
12). The genome which is replicated in the nucleus of infected cell, contains eight 
segmented single-stranded RNAs with negative polarity (ss (-) sense RNA) (13-16) of 
890 to 2,341 nucleotides each that code for at least 10 viral structure proteins (Table 
1.1. and Figure 1.2.A). The viral genomic RNA (vRNA) of IAV is complexed with the 
viral RNA-dependent RNA-polymerase (RDRP) in all negative-sense RNA viruses, 
which comprises three protein subunits (PB1, PB2 and PA) and the nucleoprotein (NP) 
into biologically active viral ribonucleoprotein complexes (vRNP) (17) assembled in a 
twisted rod (10-15 nm in width and 30-120 nm in length) (18) (Figure 1.2.B) that is 
folded back and coiled on itself (19-21). The vRNA serves as a template for both 
transcription and replication (22). The RNPs are the minimal set of infectious viral 
structures. The nucleoprotein is a major component of the RNP. The primary function 
of NP is to encapsidate the virus genome for the purposes of RNA transcription, 
replication and packaging (23). The outer surface of the virus consists of two 
glycoproteins, the hemagglutinin (HA) and the neuraminidase (NA) embedded in the 
virus lipid membrane envelope (24, 25). The HA allows the virus to agglutinate red 
blood cells and is responsible for virus binding to sialic acid (N-acetyl- or N-
glycolylneuraminic acid) containing receptors on the cell surface and red blood cells 
(26, 27) and for fusion of the viral and cellular membrane during virus entry (28-31) to 
allow the RNPs to enter into the cytoplasm of the host cells. The mature HA forms 
homotrimers of 220 kDa. Each monomer is initially present as a single polypeptide 
precursor (HA0) that is subsequently cleaved into two subunits HA1 and HA2 (32). 
These subunits are linked by a single disulphide bond between residue 14 of HA1 and 
residue 137 of HA2 [23]. The NA is the second subtype-specific glycoprotein and 
possesses enzymatic activity cleaving sialic acid residues from glycoproteins or 
glycolipids (33-35), which function as cellular receptors for attachment of influenza 
virions. The neuraminidase activity of NA mediates the release of newly formed virus 
particles from the surface of infected cells (36). Without this step, the newly forming 
virus particles immediately re-bind to their receptor and are not released into the 
extracellular space. Instead, they remain attached to the cell in large clump (37).  The 
M2 is an integral membrane protein encoded by IAV and possesses an ion channel 
activity that is required for efficient release of the viral genome into the cell cytoplasm 
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and for correct maturation of the HA. The viral matrix protein M1 is thought to underlie 
the lipid bilayer and to associate with the RNP core of the virus. It has been shown that 
export of vRNP requires the synthesis of M1 protein (13, 39, 40), nevertheless the exact 
function still remains unknown. The first protein encoded by NS-segment is the non-
structural protein NS1. It can only be found in the influenza virus-infected cells and 
functions as a major pathogenicity factor. It is known that NS1 plays an important role 
in preventing the PKR-mediated antiviral response (41). Furthermore NS1 protein 
represses interferon  (IFN) synthesis by preventing activation of the NF-kB 
signalling pathway & transcription of interferon genes (42-47). NS2 or Nuclear Export 
Protein (NEP) was originally designated as non-structural protein. It possesses a 
Nuclear Export Signal (NES) sequence, which is essential for export of vRNP from the 
nucleus  (48, 49). M1 and NS1 mRNAs are collinear transcripts, whereas M2 and NS2 
protein are generated from a spliced transcript of their genome segments. The PB1 
segment contains an alternative +1-reading frame encoding the recently discovered 
PB1-F2 protein (50), which is the only influenza virus factor identified to act 
intrinsically by localization and interaction with the mitochondrial-dependent apoptotic 
pathway. This protein is not essential in cell culture and not strongly conserved (51). 
Therefore the role of this protein in viral propagation is not well known. 
 
 
 
 
 
Introduction                                                                                                                6
 
 
 
 
 
 
 
 
 
 
Figure 1.1. The reservoir of influenza A viruses. The working hypothesis is that 
wild aquatic birds are the primordial reservoir of all influenza viruses for avian and 
mammalian species. Transmission of influenza has been demonstrated between pigs 
and humans (solid line). There is extensive evidence for transmission between wild 
ducks and other species, and the five different host groups are based on 
phylogenetic analysis of the nucleoproteins of a large number of different influenza 
viruses. (www.fiav.info).  
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Table 1.1 Influenza A virus proteins and functions (stem A/PR/8/34, H1N1) 
Modified from (256) 
 
 
 
 
 
 
 
 
 
 
Segment vRNA(nt) Protein AA Functions 
1 2341 PB2 759 subunit of  RDRP; "Cap-snatching" 
2 2341 PB1 
PB1-F2 
757 
87 
catalytic subunit of  RDRP; elongation 
not known  
3 2233 PA 716 subunit of  RDRP 
4 1778 HA 566 surface-glycoprotein;  
receptor binding; membrane fusion 
5 1565 NP 498 nucleoprotein; encapsidation of v/cRNA; part 
of transcriptase complex; nuclear/cytoplasmic 
transport of vRNA 
6 1413 NA 454 surface-glycoprotein; neuraminidase;  
receptor disruption, virus releasing 
7 1027 M1 
M2 
252 
97 
matrix protein; ion channel activity;  
protecting HA-conformation, RNP-release 
8 890 NS1 
 
 
NEP/NS2 
230 
 
 
121 
post-transcription regulator; inhibition of (i) 
pre-mRNA splicing, (ii) polyadenylation (iii) 
PKR-activation 
nuclear export factor 
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Figure 1.2 A: Schematic diagram of the influenza virion. The eight viral RNA 
segments were separated in a urea polyacrylamide gel electrophoresis and detected by 
silver staining (left). The corresponding gene products and their accepted localization in 
the virion are right indicated. NS1 is not a component of mature virions. (Adapted from 
S. Pleschka and S. Ludwig, Germany) 
 
 
 
 
 
Figure 1.2 B: The structure of influenza virus RNP. The RNP complex is the minimal 
set of infectious viral structures. It consists of (-) sense single-stranded RNA (black 
line), nucleoprotein (NP) (blue and purple) and three subunits of RNA-dependent 
RNA-polymerase (RDRP): PB1 (yellow), PB2 (orange) and PA (green). (Adapted from 
P. Digard, UK) 
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Figure 1.2 C Left: Electron micrographs of influenza virus. Spherical Influenza A 
virus particle has a diameter of approximately 100 nm. A–C: The structure of the 
internal components; D: the external view. A substantial fraction (up to 50%) of 
influenza virions contain large helical internal components (A, B), which may contain 
individual ribonucleoprotein (RNP) segments (C) linked together. The individual RNPs 
each contain a binding site for the viral polymerase, as seen by the immunogold 
labelling of the end of the RNP segment (C). The external view of the virions (D) 
illustrates the pleomorphic appearance and the surface spikes. Bar in all figures equals 
50 nm.  
Right: Budding virions show a specific arrangement of eight rod-like structures of 
different lengths. (a) Rod-like structures, 12 nm in width, are associated with the viral 
envelope at the distal end of the budding virion. (b, c) Electron-dense dots, representing 
transversely sectioned rods, were observed in each virion in a characteristic 
configuration. (d) Serial section of a virion cut from the distal end. As the distance from 
the end increased the number of dots decreased, suggesting that the eight rod-like 
structures differed in length. (e) Lower magnification views of the serial ultra-thin 
section in (d), demonstrating that the serial section shown in (d) represents the same 
virion (circled in red). Other virions are indicated by arrowheads. Scale bars, 50 nm (a, 
c, d); 200 nm (b, e).  
1.2.2 Genome replication and propagation 
The initial phase of virus infection involves the delivery of transcriptionally active virus 
RNPs to the nucleus of infected cells to initiate the expression and replication of the 
virus genome. A single replication cycle of the influenza A virus takes approximately 
8-10 hours.  It starts when the hemagglutinin- spike of influenza virions binds to the 
cellular surface receptor containing 2,3- or 2,6-galactose sialic acid linkages 
(adsorption) (52-55) and afterwards the particle is engulfed into the cell by endocytosis. 
Influenza viruses can be internalized into the cells via multiple endocytic pathways, 
      Left            Right 
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with both clathrin-mediated as well as clathrin- and caveolin-independent pathway(s) 
(56). The release of the viral genome (uncoating) takes place in acidic environment of 
the endocytotic vesicle. At about pH 5.0, a major conformational change in the HA 
spike is induced  (57). This conformational change results in movement of the fusion 
peptide sequences of HA2 allowing their insertion into the target membrane (58) . The 
altered HA draws the membranes of the virus and endosome together and they merge 
(penetration), creating a hole through which the viral contents are poured into the 
cytoplasm. The pH-activated ion channels made up of M2 protein are also important for 
uncoating (Figure 1.3.B). Once a virion particle has been endocytosed, the low pH-
activated ion-channel activity of the virion-associated M2 protein (59-61) permits the 
flow of ions from the endosome to the virion interior, which leads to the reduction of 
the pH in the virions resulting in disruption the protein-protein interactions and 
dissociation of RNPs from M1 protein (uncoating) (62-63). Besides its function to 
release the viral genome into the cell cytoplasm, M2 is also responsible for the correct 
maturation of the HA. All four proteins of the RNP complex (NP, PB1, PB2 and PA) 
contain nuclear localization signals (NLS). It has been reported that specific nuclear 
targeting sequences in the NP result in translocation of the RNPs into the nucleus via 
nuclear pore complex (NPC) (64-66), where replication and transcription of viral RNA 
(vRNA) takes place (Figure 1.3.A). Late in the virus replication cycle newly formed 
RNPs are transported from the cell nucleus to the cytoplasm through the NPC (67) to 
be prepared for packaging and budding. M1 and NEP/NS2 are known to play an 
important role in exporting the RNPs and preventing them to be reimported into the 
nucleus (68-70). After translocation of the RNPs into the nucleus of infected cell, the 
viral genome is transcribed and replicated by the RDRP (71). The NP encapsidates 
cRNAs and vRNAs, which is necessary for them to be recognized as templates for the 
viral polymerase. In the nucleus the (-) sense vRNAs are directly transcribed into viral 
(+) sense mRNAs and replicated through a complementary (+) sense cRNA 
intermediate to produce more vRNA molecules (72). Synthesis of these three RNA 
species requires different modes of initiation and termination (73-75). Synthesis of 
mRNAs is primed by short-capped RNA fragments (m7GpppNm) that are generated 
from cellular pre-mRNAs by endonucleolytic cleavage. Consequently, viral mRNA 
molecules contain a 9 to 17 nucleotide (nt) capped host-derived RNA sequence at their 
5’ ends. On the other hand, the synthesis of cRNA and vRNA molecules is initiated in a 
primer-independent manner, resulting in triphosphorylated 5’ ends  (76). Synthesis of 
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mRNAs is prematurely terminated 16 to 17 nt from 5’ end of the vRNA template at a 
sequence of 5 to 7 uridines that acts as a polyadenylation signal (77-79). The poly (A) 
tail is synthesized by the viral RNA polymerase by repeated copying of the U sequence 
(80). During the synthesis of cRNA molecules, the polyadenylation signal is ignored, 
resulting in full-length copies of vRNA (81) (Figure 1.3.C). The PB1 subunit forms the 
core of the complex and is responsible for polymerase activity. The PB2 subunit is 
involved in generation of capped RNA primers for the initiation of transcription by 
binding the cap structures of host pre-mRNA (Cap snatching) prior to their 
endonucleolytic cleavage by PB1. The PA subunit is essential for both transcription and 
replication, but its exact role in the virus replication cycle still remains unclear (82). 
Most of the proteins made (e.g. HA, NA) remain in the cytoplasm or become associated 
with the cell membrane. The PB1, PB2, PA and NP proteins migrate back into the 
nucleus, where they associate with newly-synthesized vRNA to form new RNP 
complexes. The level of free NP is thought to control whether mRNA or cRNA is 
produced, i.e. later in infection when there is a lot of NP, mRNA synthesis stops but 
cRNA synthesis continues. NP is thus a crucial switch in the replication cycle between 
expression and assembly (83).  
NS1 is a multifunctional protein, which plays a key role in the pathogenesis of 
influenza A virus (84-86). It inhibits splicing and polyadenlation of the cellular pre-
mRNAs and nucleocytoplasmic export of cellular mRNAs and thereby keeps the 
cellular mRNAs in the nucleus (87-94). The synthesis of cellular proteins is practically 
switched off approximately three hours after viral infection (host cell shut off 
mechanism). At the same time viral proteins are efficiently translated. Although the 
details of this mechanism are not completely understood, it is sure that the NS1 plays a 
crucial role. The influenza A NS1, which has RNA-binding activity (95-96) binds to 
double stranded RNA (dsRNA), a viral replication by-product that activates protein 
kinase R (PKR)  (97-99) and thereby represses interferon  (IFN ) synthesis [37], one 
of the most potent antiviral cytokines (100). Thereby it can prevent activation of the 
transcription factors NF-kB, IRF-3 and the JNK effectors c-Jun and ATF-2 that are 
essential for (IFN )-expression (101-105). The dsRNA-dependent PKR (106-108) is 
part of interferon-induced host defence against viral infection (109). Normally activated 
PKR phosphorylates the translation-elongation factor 2 (elF-2) and thereby stops the 
translation procedure. Other data show that the IFN antagonistic NS1 protein down-
regulates apoptosis, indicating anti-apoptotic potential (110). NA, M2 and the HA 
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precursor (HA0) are transported via the ERK and the Golgi/trans Golgi-Network to the 
cell membrane in a signal recognition particle (SRP)-dependent manner (111). In 
epithelial cells, HA is transported to the apical domain of the plasma membrane (112). 
In the course of transport to the cell surface (maturation), HA undergoes a series of 
post-translational processing reactions that include polypeptide folding (113), 
trimerization (114), N-glycosylation (115), acylation (116) and proteolytic cleavage 
(117). Infectivity requires proteolytic cleavage of the HA precursor into the disulfide-
linked cleavage products HA1 and HA2 (118-124). Due to the newly generated N-
terminus of HA2, the fusion peptide is available to trigger the fusion of viral membrane 
and cellular membrane (125). Normally different proteases are able to cleave the HA0, 
but it depends on the amino acid (aa) sequence at the HA0 cleavage site. It was 
proposed that the cleavage site would correlate with the virulence of the virus and that 
virulent strains (e.g. H5 and H7) would contain a furan intracellular protease 
recognition motif, whereas the avirulent strains would contain only a single arginine 
residue used by extracellular proteases (126-127). The mature glycoprotein HA and NA 
and the nonglycosylated M2 are transferred to the cellular membrane as a trimer (HA) 
and/or as tetramers (NA, M2). In the nucleus M1 and NEP bind to the RNPs and are 
exported to the cytoplasm through the NPC. For the further maturation (assembly) the 
M1 retains the RNPs in the cytoplasm (128). Nuclear export of RNPs has been shown 
to depend on viral M1 and NEP, and on cellular factors CRM1, Ran-GTP and other 
potential factors (129-132). Afterwards RNP together with other viral protein in the 
membrane will be enwrapped with the cellular membrane and released through 
budding. The enzymatic activity of the NA is required for the virus release from the 
infected cells by cleaving the sialic acid from virus and cell surface glycoconjugates 
(receptors) (133-136). The packaging mechanism responsible for sorting eight distinct 
genome segments into each particle is not a purely random process (137-138). It has 
been reported that the packaging signal of vRNA molecules already occurs in the 
nucleus or during nuclear export through the process of vRNP/cRNP discrimination 
involving the binding interactions of viral polymerase with either of the two differently 
bulged vRNA and cRNA promoter structures (139. Additionally, an RNA hybridization 
study showed that only vRNA molecules and no cRNA molecules are found outside the 
nucleus in the cytoplasm (140). Furthermore it has recently been found that the RNPs 
of influenza A virus are organized in a distinct pattern, in which the individual RNPs 
are suspended from the interior of the viral envelope at the distal end of the budding 
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virion and are oriented perpendicular to the budding tip (141) supporting the data for a 
model of a selective incorporation of viral RNA segments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 A: Replication cycle of influenza virus. It starts when the HA-spike binds 
to its cellular receptor determinant on cell surface. The virion is then taken into the cell 
through endocytosis. After the fusion between the viral and the endosomal membrane, 
the RNPs are released into the cell cytoplasm and afterwards transported into the 
nucleus, where transcription and replication of the viral RNA takes place. The viral 
mRNA is subsequently exported to the cytoplasm and translated into viral proteins. The 
explicative proteins like NP and polymerase proteins are transported back to the 
nucleus and continue the genome replication. The viral surface-glycoproteins (e.g. HA 
and NA) are transported to the cell surface and modified by various post-translational 
processing. Late during virus replication cycle RNPs are exported out of the nucleus 
and packaged into new enveloped virions that are released from the membrane of 
infected cell through budding. (Adapted from S. Pleschka, Germany) 
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Figure 1.3 B: Schematic diagram of the proposed role of the M2 ion channel 
activity in virus entry. The M2 ion channel activity is thought to facilitate the flow of 
protons from the lumen of the endosome into the virion interior, bringing about 
dissociation of protein-protein interactions between the HA cytoplasmic tail and M1, 
M1, and lipid or RNPs and M1 from the RNPs.  
 
Figure 1.3 C: Replication and translation process of vRNA. PB2 attaches to the 
m7G cap of host mRNAs. This structure is then cleaved from the cellular mRNA by 
PB1, remaining attached to PB2. The cap serves as a primer for RNA synthesis. The (-) 
sense vRNAs are directly transcribed into (+) sense mRNAs and replicated through 
producing (+) sense cRNAs to synthesize more vRNA molecules. 
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1.2.3 Antigenic variation of influenza virus infection (antigenic shift and drift) 
The three types of influenza viruses (A, B and C) vary greatly in their epidemiological 
significance. The epidemiology of influenza A viruses has been well studied in relation 
to the occurrence of epidemics and pandemic episodes of disease in humans. The 
continuing occurrence of influenza epidemics is caused by rapid evolution of the viral 
genome. This can be monitored by antigenic analyses and sequence analysis of genes, 
particularly the hemagglutinin gene. 
Influenza A virus infection has two phenomena; the first being the almost identical 
annual epidemics which occur in most countries and the second are the extensive 
pandemics which occur approximately every 10-30 years (NIH, Report on Flu, 2005). 
It is apparent that pandemics are due to the appearance of new influenza A subtypes 
against which the population has no immunity. This phenomenon is known as 
“antigenic shift” (187-188). As immunity to the new subtype by producing virus-
neutralizing antibodies against the hemagglutinin (HA) protein builds up, further 
epidemics are more limited. The HA antigen is always involved in antigenic shift as it 
is responsible for eliciting virus-neutralizing antibodies (189-191). There are three 
possibilities as to how antigenic shift can occur (CDC, Focus on Bird Flu, 2005). 
(I) Reassortment: The most widely held view is that the new virus subtypes are 
reassortant viruses resulting from double infection, where eight RNA segments of each 
swap with each other, producing a new virus. Pigs are thought to provide the "mixing 
vessel" for AIV and human influenza virus where genetic reassortment may occur 
(192-195).  
(II) Recirculation of existing subtypes: In 1977 H1N1 reappeared which was very 
similar to the strain which circulated before 1957. It was widely believed that it may 
have escaped from a laboratory (196). As a sizable proportion of the population had 
already been exposed to the H1N1 virus before 1957, it did not cause a pandemic. 
(III) Gradual adaptation of animal viruses to human transmission: These are small 
changes in the virus that happen continually over time caused by missense mutation. 
One reason for this is the lack of proofreading mechanism in the RNA replication, 
resulting in error rate of one in 10,000 nucleotides (197). Spontaneous mutations in the 
HA (or NA) gene give their owners a selective advantage as the host population 
becomes increasingly immune to the earlier strains. These antigenic changes are known 
as “antigenic drift” (Figure 1.5.). Epidemics due to new virus strains arising from 
antigenic drift are not as severe as for those showing antigenic shift, since partial 
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immunity is present in persons with cross-reacting antibody induced by previous 
infection. 
 
1.3 Avian influenza viruses 
The first avian influenza (AI) virus was isolated in 1902 (142), although it was not 
identified as a member of influenza A virus family until 1955. Influenza viruses have 
been isolated from domestic poultry suffering from highly pathogenic avian influenza 
(fowl plague) and from apparently healthy wild birds, including waterfowl. 
Fowl plague viruses (FPV) were used for this work representing a model of type A 
influenza viruses. AI is a highly contagious viral infection, which can affect all species 
of birds and can manifest itself in different ways depending mainly on the 
pathogenicity of the virus involved and on the species affected. IV that infects birds are 
called “avian influenza viruses” (AIV) and only IAV can infect birds. In waterfowl, 
influenza is always asymptomatic and birds regularly shed large amounts of the virus. 
They seldom get sick, while other small mammals that contact the influenza virus are 
infected and may die. It appears that birds have established a coexistence with the 
influenza virus. Through co-evolution, birds and the influenza virus are optimally 
adapted to one another. 
 
1.3.1 History of avian influenza  
The AI has captured considerable international attention over the past years with 
serious epidemics of this disease affecting almost all areas in Southeast Asia since 
1997. Now considered an avian pandemic, serious outbreaks of AI had also affected the 
Netherlands, Belgium, and Germany in 2003 (149-150). The AI was first recorded in 
Italy more than 100 years ago in 1878 as described by Perroncito et al. This highly 
pathogenic avian influenza is characterized by sudden onset of severe disease, rapid 
contagion, and a mortality rate that can approach 100% within 48 hours (151-153). As 
the cause of massive poultry epidemics, this disease was then known as “Fowl Plague”. 
The causative agent of this disease was isolated from a chicken in 1902, marking the 
first documented isolation of influenza virus (154). In 1955, it was determined that the 
virus causing Fowl Plague is influenza A virus (157). The AIV particle is characterized 
by the surface glycoproteins hemagglutinin (HA) of the H7 or H5 type. 
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1.3.2 Direct transmission 
Direct transmission from birds to human is also possible. In 1997 HPAI H5N1 was 
isolated for the first time from a human patient in Hong Kong (176-178). The virus 
infected 18 patients after close contact with poultry, resulting in six deaths (176, 
178,179). Within three days, Hong Kong's entire chicken population was slaughtered to 
prevent further outbreak (180). Recently HPAI H7N7 broke out in Netherlands in 2003 
(176, 181) and spread to Belgium and Germany and resulted in the culling of 30 million 
chickens. The virus infected 83 people causing conjunctivitis and flu-like symptoms, 
and caused the death of one veterinarian (182-183). After 1997 and 2003, a major 
outbreak of HPAI subtype H5N1 surfaced again in Vietnam’s and Thailand’s poultry 
industry in the early 2004 accompanied with human cases (183). Within a few weeks, 
the disease had spread to other ten countries and regions in Asia. From the 173 cases of 
avian flu in humans, 93 were fatal (WHO, 2007). Vietnam has seen the most cases thus 
far 93 in total with 42 fatal infections. Cumulative no. of H5N1 cases are 50 as a total 
and 33 death reported by WHO (2007) 
Though scientists determined that the spread of the AIV from birds to humans are rare 
occurrences, they were also quick to express grave caution that this problem could 
become significantly worse if the virus mutated into a more lethal form, or a form that 
could pass easily from humans to humans. The WHO is particularly concerned about 
the avian virus' potential to swap genes with a common influenza virus, creating a 
lethal form of the virus that could spread around the globe within months. From 1997 to 
2007 human cases have been reported in more than 15 countries, most of which are in 
Asia (WHO, April 2007). Taken together, the death toll associated with the 1918 
influenza virus correlated to the current population could be between 180 million and 
360 million human deaths globally (184-185).  
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Figure 1.4.: Postulated evolution of the influenza A viruses currently circulating in 
humans. Serological archaeology assumes that H2N2 and H3N8 influenza viruses 
circulated in humans in 1889 and 1900, respectively. Phylogenetic evidence suggests 
that an influenza virus possessing eight gene segments from avian influenza reservoirs 
was transmitted to humans and pigs before 1918 and replaced the 1900 strain. This 
virus was probably carried from North America to Europe by American troops and 
caused the catastrophic influenza pandemic of 1918. In 1957 the Asian pandemic virus 
acquired three genes (PB1, HA, and NA) from the avian influenza gene pool in wild 
ducks by genetic reassortment and kept five other genes from the circulating human 
strain. After the Asian strain appeared, the H1N1 strains disappeared from humans. In 
1968 the Hong Kong pandemic virus acquired two genes (PB1 and HA) from the duck 
reservoir by reassortment and kept six genes from the virus circulating in humans. After 
the appearance of the Hong Kong strain, the H2N2 Asian strains were no longer 
detectable in humans. In 1977 the Russian H1N1 influenza virus that had circulated in 
humans in 1950 reappeared and spread in children and young adults. This virus 
probably escaped from a laboratory and has continued to co-circulate with the H3N2 
influenza viruses in human population.  
1.4 The progress of reverse genetic systems for influenza viruses 
The reverse genetics techniques for influenza viruses have enabled the construction of 
IV that contains altered genomes. The ability to introduce attenuation characteristics 
into the viral genome holds the promise for developing a live attenuated influenza virus 
for vaccination 
Reverse genetics techniques that permit the site-specific genetic manipulation of 
negative-strand viruses were first established the group of P. Pales in 1989 (143). In the 
initial experiment, in vitro reconstituted NA-specific RNPs were transfected into cells 
which were then infected with helper influenza A virus (144). Specifically, the RNPs 
were generated in vitro by mixing synthetic RNA transcribed from cDNA and purified 
NP protein and viral polymerase proteins. 
An alternative method developed by S. Pleschka of introducing site-specific mutations 
into the influenza virus genome is based on the intracellular reconstitution of RNP 
complexes derived from plasmid-based expression vectors. In this system, influenza 
virus RNA transcripts are derived from plasmids, which are transfected into cells. 
Genomic or antigenomic viral transcripts are generated via cellular polymerase 
promoter at the 5
’
 end of the viral gene (145), and a ribozyme sequence that generates 
the desired 3
’
 end by autocatalytic cleavage. Co-transfection with plasmids expressing 
the viral polymerase proteins PB1, PB2, PA and NP protein results in the 
encapsidation, transcription and replication of the expressed viral RNAs. The co-
transfected cells are then infected with helper influenza virus, which takes up the 
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intracellularly reconstituted RNPs. In contrast to the RNP transfection system this 
plasmid-based transfection system eliminates the need for purification of the viral NP 
and polymerase proteins which is required for in vitro reconstitution of RNP complexes 
(146). 
It has been shown that co expression in mammalian cells of all eight influenza virus 
genes and viral NP and polymerase proteins from plasmids results in the generation of 
recombinant viruses. Due to the segmented nature of the genome of influenza viruses, 
more than one plasmid is required to express the eight viral RNA segments.  
 
1.5 Influenza vaccines and antivirals 
Yearly vaccination with the flu vaccine is the primary strategy for preventing 
complications of influenza virus infections. It is remarkable that the first attempts to 
inject an influenza virus into humans were made only 2 years after the first isolation of 
human influenza virus from an infected ferret in 1933 (3). These studies were not 
originally designed to develop a vaccine, but were to investigate whether live influenza 
virus grown in chick embryos would infect humans and induce antibody after 
subcutaneous injection (4). It was observed that neutralizing antibodies developed in 
serum, peaked after 2 weeks and persisted for unto 6 months. 
Antiviral medications with activity against influenza viruses can be effective for the 
prevention and treatment of influenza. They are relatively harmless to the host, and 
therefore can be used to treat infections. There are adamantanes (amantadine and 
rimantadine) that are licensed in the U.S for the treatment and prevention of influenza. 
The mechanism of action of these two drugs is inhibition of acid activation of the M2 
ion channel that normally results in acidification of the interior of the virion with 
dissociation of the M1 matrix protein from the ribonucleoprotein complex (uncoating) 
so that transport of the ribonucleoprotein complex to the nucleus that is a requisite step 
for genome transcription, translation and assembly, can not occur. Resistance of 
influenza A viruses to admantanes in vitro was described in the initial reports of the 
antiviral effects of these drugs (267,268). In 1981, two strains of H3N2 virus were 
relatively resistant to amantadine and rimantadine. 
However, because a high proportion of circulating influenza viruses in the U.S. in 
recent years have been resistant to the adamantanes, CDC recommends that neither 
amantadine nor rimantadine be used for the treatment or chemoprophylaxis of influenza 
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in the United States during the 2007-08 influenza season. Two licensed influenza 
antiviral agents are recommended for use in the United States during the 2007-08 
influenza seasons (1) Oseltamivir and (2) Zanamivir. These are chemically related 
antiviral medications known as neuraminidase inhibitors that have activity against both 
influenza A and B viruses. 
These drugs have mechanism of action towards the inhibition of virus release by 
destroying neuraminidase, which is required for the release of the new progeny 
infectious virus. Oseltamivir is approved for treatment of persons aged 1 year and 
older. Zanamivir is approved for treatment of persons aged 7 years and older. The two 
medications differ in pharmacokinetics, adverse events, and routes of administration, 
dosages, and costs.  
  
1.6 Signal transduction and influenza viruses 
1.6.1 Mechanisms of intracellular signal transduction 
There are approximately 10
14
 cells in human body. In order to keep each organ 
functional, every single cell must be able to react both to the external stimulus 
including physical and mechanical signals and to the signals from other cells. This 
mechanism requires the recognition, processing and passing on signals via intracellular 
signalling pathways that regulate the cell metabolism, differentiation and proliferation 
(201-203). 
The cellular response to growth factors, inflammatory cytokines, and other mitogens is 
often mediated by receptors that either are G-protein-coupled receptor (GPCR) or 
intrinsic protein receptor tyrosine kinases (RTK) (204). The binding of the ligand to 
receptor tyrosine kinases induces dimerization and autophosphorylation (activation) of 
the kinases. The activated tyrosine kinase binds to and phosphorylates an adaptor 
protein, such as Grb2, that, in turn, activates a guanine-nucleotide exchange factor, 
such as mammalian son-of-sevenless (mSOS), that, in turn, activates a small GTP-
binding protein, such as Ras or Rac (202). The GTP-binding proteins then transmit the 
signal to one of several cascades of protein serine/threonine kinases that utilize the 
sequential phosphorylation of kinases to transmit and amplify the signal (205). These 
kinase cascades are collectively known as mitogen-activated protein kinase (MAPK) 
signaling cascades (206-108). ERK has been the best characterized MAPK and the 
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Raf/MEK/ERK pathway represents one of the best characterized MAPK signaling 
pathways (208, 209) over a dozen MAPKs organized in at least four different families 
have been identified in mammals (208). They are activated via phosphorylation 
catalysed by distinct upstream kinases on both tyrosine and threonine residues within 
their catalytic domains. These processes are vital to the cells; therefore a high degree of 
homology exists between divergent species. In mammalian cells, three distinguishable 
MAPK modules have been well described now known as the ERK (extracellular signal-
regulated kinase), JNK (c-Jun N-terminal kinase) and the p38/MAPK pathways (208). 
The MAP kinase lies within protein kinase cascades. Each cascade consists of no fewer 
than three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a 
MAPK kinase (MAPKK) and a MAP kinase (MAPK) (Figure 1.6.). Currently, at least 
14 MAPKKKs, 7 MAPKKs and 12 MAPKs have been identified in mammalian cells 
(208) (Table 1.2.). These pathways regulate a variety of responses including cell 
growth, differentiation, adaptation to the environment, as well as apoptosis (210-212). 
The MAPKs also control numerous regulatory processes during development and 
homeostasis (213-215). The mammalian ERK module, also known as the classical 
mitogen cascade, consists of serine/threonine kinase Raf, the dual-specificity kinase 
MEK and the classical MAPK ERK. For both MEK and ERK, there exist two isoforms 
(MEK1/2 and ERK1/2) while three isoforms, A-, B- and C-Raf are known for the Raf 
kinase.  
 
Table 1.2: Components of MAPK pathways in mammalian cells  
 
MAPKKK MAPKK MAPK 
Raf-1, A-Raf, B-Raf, Mos, 
TAK1, MUK, SPRK, MST, 
MEKK1, MEKK2, 
MEKK3, MEKK4, Tpl-2, 
ASK 
MEK1 (MKK1), MEK2 
(MKK2), MEK5, MEK3, 
MEK4, MEK6, MKK7 
ERK1, ERK2, p38, p38, 
p38, p38, JNK1, JNK2, 
JNK3, ERK3, ERK3, 
ERK4, ERK5 
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Figure 1.5.: MAP kinase cascade in mammalian cells. Mitogen-activated protein 
kinases (MAPK) are a family of Ser/Thr protein kinases widely conserved among 
eukaryotes and are involved in many cellular programs such as cell proliferation, cell 
differentiation, cell movement and cell death. MAPK signaling cascades are organized 
hierarchically into three-tiered modules. MAPKs are phosphorylated and activated by 
MAPK-kinases (MAPKKs), which in turn are phosphorylated and activated by 
MAPKK-kinases (MAPKKKs). The MAPKKKs are in turn activated by interaction 
with the family of small GTPases and/or other protein kinases, connecting the MAPK 
module to cell surface receptors or external stimuli.  
 
1.6.2 The Raf/MEK/ERK pathway (MAPK signalling cascade) 
The Raf/MEK/ERK signalling cascade becomes strongly activated by mitogenic 
stimuli such as growth factors (210-212). This signalling pathway transduces signals 
leading to growth or differentiation in cells. Binding of a growth factors e.g. epidermal 
growth factor EGF) to the corresponding receptor tyrosine kinase RTK) leads to its 
oligomerisation and subsequent autophosphorylation (202, 216). Phosphorylated 
tyrosines on the intracellular part of receptor, serve as docking sites for the SH2-
domain (Src homology) of adapter protein the GrB2, which itself binds via its SH3-
domain to the proline rich motif of the GDP-GTP exchange factor Sops (son of 
sevenless). SOS interacts with Ras and activates the exchange of GDP to GTP (217-
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220). GTP loaded Ras leads to the recruitment to the cell membrane of the cytosolic 
serine/threonine kinase Raf, a membrane shuttle kinase identified as an oncogenic 
product of the murine sarcomavirus (221-225). This translocation results in the 
activation of the membrane associated Raf. Ras-Raf interaction alone, however, is not 
sufficient to activate Raf completely (226-228). Activation mediated by multiple 
kinases like Src, PKC (protein kinase C) and PAK (p21 (Rac/Cdc42)-activated protein 
kinase) leads to phosphorylation and positive regulation of Raf (230-234), whereas 
other kinases like PKA (protein kinase A) down regulate Raf activity (235). The first 
characterized substrate of Raf isoenzymes was the dual specificity kinase MEK (236). 
Once activated, MEK transduces the signals through phosphorylation on T-E-Y-motifs 
in the MAP-kinases ERK1 (p44) and ERK2 (p42) (237, 238) (Figure 1.7.). ERK 
phosphorylation increases its catalytic activity, mediates oligomerisation and alleviates 
the shuttling of the kinase to the nucleus. ERKs are nuclear shuttle kinases and have 
several described substrates in contrast to its upstream activators Raf and MEK. ERK 
target proteins are e.g. serine/threonine kinases like 3pK, ribosomal S6 kinase 
(RSK1p90) also known as MAPKAP-kinase 1, RNA-polymerase II, phospholipase A2 
and several transcription factors like, Elk-1 and c-Jun (226, 239-242). ERKs are 
essential elements of mitogenic signalling. Prolonged activation and nuclear retention 
of ERKs is required for transcription of the cyclin D1 gene (243), suggesting a 
mechanism of ERK-mediated enhancement of cell cycle entry. ERKs are also 
associated with cytoskeleton (244), playing a putative role in cytoskeleton 
reorganisation. Expression of constitutively active components of the pathway causes 
cell transformation (245).  
 
Introduction                                                                                                                24
 
Figure 1.6.: Activation of Raf/MEK/ERK (MAPK) signaling cascade (simplified). 
The G-protein coupled receptors (GPCR) and receptor tyrosine kinase (RTK) are the 
acceptor of extra-cellular stimuli localized in the plasma membrane. After cell receptor 
stimulation the signal from GPGR is transmitted via G-Protein (Gq) to phospholipase 
C (PLC), which afterwards cleaves phosphatidylinositol-4, 5-Bisphosphat (PIP2) in 
inositol-1, 4, 5-trisphosphat (IP3) and Diacylglycerol (DAG). IP3 diffuses into cytosol 
and binds on its receptors that are localized on endoplasmic reticulum. This leads to 
release of calcium-ion (Ca
2+
) from intra-cellular storage. The Ca
2+
-channel (CRAC) in 
the plasma membrane is consequently activated and contributes to the increase of 
cytosolic Ca
2+
-ion. The Protein-Kinase C (PKC) is subsequently activated by DAG and 
increased Ca
2+
-concentration. Moreover the extra-cellular stimuli are conveyed via 
Grb2/sos complex to Ras. Both, activated Ras as well as PKC can lead to an activation 
of Raf/MEK/ERK (MAPK) signalling cascade (blue lines). Afterwards ERK1/2 is 
translocated to the nucleus and interacts with transcription factors to change the gene 
expression (249-251). (Figure adapted from S. Kötter, Germany). 
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1.6.3 Virus-induced Raf/MEK/ERK (MAPK) signalling cascade is essential host 
function for influenza A virus propagation 
Replication and transcription of the influenza virus genome takes place exclusively 
within the nucleus of the infected cells (252). Late in the infectious cycle the RNPs are 
exported from the nucleus to the cell membrane to be enwrapped into budding progeny 
virions (252-254). During their replication influenza viruses interacts with many 
different cellular functions to promote their propagation (255, 256). Among the 
different signalling processes activated by influenza virus infection, the Raf/MEK/ERK 
(MAPK) signalling cascade plays a crucial role for efficient virus propagation. This 
pathway is activated late during influenza virus replication cycle and is required for an 
efficient nuclear RNP export (Figure 1.7) (252-254). Analysis of this MAPK signalling 
cascade has been facilitated by the use of highly specific MEK-inhibitors (257, 258). It 
was shown that a block of this signalling cascade impairs nuclear RNP export and virus 
replication without the emergence of resistant variants (254, 255). In addition, influenza 
virus replicate more efficiently upon selective induction of Raf/MEK/ERK signalling 
cascade in vivo by expression of a constitutively active version of Raf (259). 
 
 
 
 
 
 
RNP-
Export
Raf
MEK
ERK
vRNA (-)
cRNA (+)
mRNA
Translation
Posttranslational
Processing
Packaging
Introduction                                                                                                                26
Figure1.7: Raf/MEK/ERK (MAPK) cascade is activated by influenza virus. Virus-
induced MAPK signalling pathway is induced late during viral replication cycle. 
Nuclear RNP export is dependent on this cellular mechanism [196-198]. (Adapted from 
S. Pleschka, Germany). 
1.6.4 Role of virus induced calcium dependent PKC signal transmission  
Data in the literature suggests that after IAV infection influx of Ca
2+
 is accelerated and 
Ca
2+
 accumulates in the infected cells (260). The virus induces a respiratory burst in 
which H2O2 (but not O2-) are formed. Preceding the respiratory burst, a rise in 
intracellular calcium (Ca
2+
) is noted, but both responses are nearly independent of extra 
cellular Ca
2+
. The Ca
2+
 increase is paralleled by inositol-1, 4, 5-triphosphate (IP3) 
generation, implying that it is the result of phospholipase C (PLC) activation. The virus 
also elicits membrane depolarization, which is independently mediated from the Ca
2+
 
increase and respiratory burst and may reflect protein kinase C (PKC) activation (261). 
There are 12 isoforms of PKCs and these are classified in three categories (1) Classical 
or Conventional (, , ) (2) Typical and (3) Atypical. Classical PKCs are calcium 
dependent kinases and PKC is one of them. Ca2+ and DAG activate classical PKCs. 
PKC and or  are activated when human polymorphonuclear leukocytes (PMNL) are 
incubated with influenza virus (262). 
PKCII isoform is activated in early Influenza viral replication but not PKC (263). 
PKC-inhibitors reduce virus entry if added early in infection (Root et al., 2000). 
Calcium increase is blocked by L-type calcium channel blockers (CCB) Verapamil 
which inhibits influenza virus replication if added late in replication cycle (264). CCB 
blocks calcium channels in the endoplasmic reticulum therefore calcium influx from 
internal calcium store to cytoplasm is inhibited and therefore PKC mediated signaling 
might be negatively effected. We have recently shown that viral hemagglutinin 
membrane accumulation
 
and its tight association with lipid-raft domains triggers 
activation
 
of the MAPK cascade, which seems to involve protein kinase C  activation 
(265). 
 
1.6.5 Protein kinase C as a therapeutic target  
PKC is a viable target for development of novel therapeutics against cardiac diseases, 
cancer, viral infections or other diseases as it is intricately involved in the processes 
that mediate disease pathogenesis. PKC is a family
 
of serine/threonine kinases that 
regulate a variety of cell
 
functions including proliferation, gene expression, cell cycle,
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differentiation, cytoskeletal organization cell migration, cell behaviors and
 
apoptosis. 
The PKC family was the first recognized receptor
 
of diacylglycerol. Aberrant PKC 
activation can lead to diseases
 
of cellular dysregulation such as cancer and diabetes. 
Activation of PKC by phorbol esters promotes tumor formation, and from that it is 
concluded that inhibitors of classical PKC might prevent carcinogenesis or inhibit 
tumor formation (198). Strategies that serve to alter classical PKC function may prove 
to be useful in the treatment of numerous disease states. Further examination of 
downstream effectors of PKC showed that extra cellular signal-regulated kinase (ERK) 
is critical for angiogenesis, and is accordingly phosphorylated in response to PMA. 
Surprisingly however, phosphorylation of ERK is dependent of PKC activity (200). 
 
1.6.6 Calcium channel blocker (Verapamil) 
Verapamil is a calcium channel blocker. Increased concentrations of cytosolic Ca
2+
 
causes increased contractions of the myocardium and vascular smooth muscle. The 
entry of extracellular Ca
2+
 is more important in initiating the contraction of myocardial 
cells, while the release of Ca
2+
 from intracellular storage sites also participates in 
vascular smooth muscle, particularly in some vascular beds. In addition, the entry of 
extracellular Ca
2+ 
can trigger the release of additional Ca
2+ 
from intracellular stores. 
Verapamil not only reduces the magnitude of Ca
2+
 current through the slow channel, 
but also decreases the rate of recovery of the channel. In addition, channel blockade 
caused by Verapamil is enhanced as the frequency of stimulation increases. Verapamil 
depresses the rate of the sinus node pacemaker and slow atrio-ventricular conduction; 
the later effect is the basis for its use in the treatment of supraventricular 
tachyarrhythmias. Therefore Verapamil is used in cardiovascular diseases (heart attack, 
high blood pressure and angina pectoris) therapy in humans. 
 
1.7 Aim of the project 
The aim of my project was to investigate the role of PKC for efficient influenza virus 
replication  and its part in activation of influenza virus-induced Raf/MEK/ERK 
(MAPK) signalling cascade which is essential host function for RNP-export and 
therefore for the production of infectious progeny virus. This signalling cascade is 
activated late in the influenza virus replication cycle and nuclear RNP export is 
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dependent on this cellular function. In influenza virus infected cells calcium 
concentration (Ca
2+
) is increased and therefore the calcium dependent cellular factor 
PKC could be one of the upstream kinases responsible for the activation of 
Raf/MEK/ERK signalling. Therefore I wanted to investigate the inhibitory effect of 
Verapamil on virus-induced calcium-dependent PKC transmitted Raf/MEK/ERK 
signalling, RNP-export and virus replication. Additionally I wanted to analyze the 
effect of Verapamil on viral protein production and viral transcription.  
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2. Materials and Methods  
2.1 Materials  
2.1.1 Chemicals and reagents 
Acrylamide                  Bio-Rad, USA 
Acrylamide/bisacrylamide 30, 30%, 37.5:1    Roth, Germany 
Acrylamide/bisacrylamide 40, 40%, 19:1    Roth, Germany 
Acetic acid        Roth, Germany 
Agarose ultra pure        Roth, Germany 
Ammonium persulfate (APS)     Serva, Germany 
Ampicillin        ICN, USA 
Agar high-gel strength      Serva, Germany  
Boric acid        Roth, Germany 
Bromophenol blue       Merck, Germany 
Chloroform        Roth, Germany 
Coomassie brilliant blue R 250     Merck, Germany 
Dimethylsulfoxid (DMSO)      Sigma, USA 
1,4-Diazabicyclo [2,2,2]octane (DABCO)    Merck, Germany 
DEAE Dextran (Mw, 500,000)     Pharmacia  Biotech 
Di-Sodium hydrogen phosphate anhydrous (Na2HPO4) Merck, Germany 
Ethanol (absolute)        Roth, Germany 
Ethidium bromide        Roche, Germany 
Ethylenediamine tetraacetic acid (EDTA)     Fluka, USA 
Extract of yeast powder      Merck, Germany 
Formamide        Fluka, USA 
Glycerol        Sigma, USA 
Glycogen         Roche, Germany  
Isoamyl alcohol        Roth, Germany 
Isopropanol         Roth, Germany 
Magnesium chloride (MgCl2)      Merck, Germany 
Mowiol 40 - 88       Aldrich, Germany 
Methanol        Roth, Germany 
N-2-hydroxyethylpiperazine (HEPES)     Sigma, USA 
Oxoid Agar        Oxoid, England 
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Peptone from meat trypsin-digested     Merck, Germany 
Potassium chloride (KCl)      Roth, Germany  
Potassium dihydrogen phosphate (KH2PO4)    Roth, Germany  
Roti-phenol         Roth, Germany 
Roti-phenol/ chloroform      Roth, Germany 
Sodium acetic acid (NaAc)      Roth, Germany 
Sodium chloride (NaCl)      Roth, Germany 
Sodium dodecyl sulfate (SDS)     Merck, Germany 
Sodium hydroxide (NaOH)      Merck, Germany 
Sodium borohydride NaBH4)     Roth, Germany 
Sodium hydrogen carbonate (NaHCO3)    Fluka, USA 
Sodium citric acid       Roth, Germany 
Silver nitrate        Merck, Germany 
Tris base        Roth, Germany 
N, N, N’, N’-Tetramethyl-ethylene diamine (TEMED)   Serva, Germany 
Urea         BRL, USA 
ß-mercaptoethanol                               Roth, Germany 
Xylene cyanole       Sigma, USA 
 
 
2.1.2 Instruments  
Bio Imaging Analyzer (BAS 2000)     Fuji Film  
Bacterial incubator and shaker (CH 4103)    Infors AG 
Cell culture microscope      Hund Wetzlar   
Cell culture incubator Heraeus;      Nuaire  
Confocal laser scanning microscopy (DM IRBE)   Leitz  
Culture Hood (HB2448)                                                                   Heraeus  
Developing machine Optimax,     Protec  
DNA-Spectrophotometer GeneQuant II   Pharmacia Biotech  
Electrophoresis apparatus system                   Institute for Medical 
Virology  
Electrophoresis power supply (EPS500/400 Pharmacia  
ELITE analyzer  Beckman Coulter  
ELISA reader (Type LP 400)     Diagnostic Pasteur  
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FACS Caliber        Becton Dickinson  
Fine scale (Mettler PM460)      Mettler Waagen  
Gene Pulser        Biorad  
GeneQuant II (RNA/DNA calculator)    Pharmacia Biotech  
Heat block        Jumotron  
Magnetic stirrer       IKA Labortechnik  
Mega centrifuge (J-TB-024D) Beckman  
Megafuge 1.0 R                     Heraeus  
Microplate Luminometer         Molecular Devices  
Microwave oven                                                            Quelle  
Mini centrifuge Biofuge 13,                                       Heraeus  
PCR machine (GeneAmp, PCR system 2400)                 Perkin Elmer  
pH meter (Type 632)                                       Metrohm  
Photo system for gel (P93D)                 Mitsubishi  
Shaker (Type 301)       MSGV GmbH  
Scale (P1200)                                                   Mettler  
Scanner Canoscan LiDE30/N1240U     Canon  
SDS-PAGE system       Institute for Medical  
Virology  
Sonicator (Type HD70)      Bondelin Sonoplus  
Spectrophotometer (DU-70)      Beckman  
Speed Vac (SPD111V)      Savant  
Thermomixer        Eppendorf  
UV light source       Vilber Lourmat  
Vortex (Vibrofix VF1)      IKA Labortechnik 
Western-Blot chamber                                                        Institute for Medical  
Virology   
Water bath (SW-20C)      Julabo  
 
2.1.3 Enzymes and enzyme inhibitor 
Restriction endonucleases       NEB, England  
RNase inhibitor (RNasin, 40U/l)     Promega, USA 
2.1.4 Nucleotides and reaction buffer 
DNA ladder mix       PEQLAB, Germany 
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10x restriction enzyme buffer 1, 2, 3 and 4    NEB, England 
10x RQ1 DNase buffer      Promega, USA 
Tris-HCl buffer for flash cat assay (pH 7.4)    Stratagene, Germany 
Bio-Rad protein assay buffer      Bio-Rad, USA 
Cell lysis buffer        Promega, USA 
 
2.1.5 Plasmids 
Dn-PKC 
Dn-Ras 
pPOL1-GFP-RT 
pPOL1-CAT-RT 
pHMG-PB1 
pHMG-PB2 
pHMG-PA 
pHMG-NP 
  
2.1.6 Kits 
QIAGEN plasmid maxi kit      QIAGEN, Germany 
QIAGEN plasmid midi kit      QIAGEN, Germany 
QIAGEN RNA/DNA mini kit     QIAGEN, Germany 
QIAprep spin miniprep kit      QIAGEN, Germany 
Flash CAT Non-Radioactive CAT Assay Kit   Stratagene, USA  
 
2.1.7 Solutions for plasmid DNA isolation 
Solution I 
Glucose                                         50 mM 
Tris.Cl (pH 8.0)                            25 mM 
EDTA (pH 8.0)                             10 mM 
Autoclaved for 15 min at 10 lb/sq.  
Solution II 
0.2 N NaOH (freshly diluted from a 10 N stock) 
1% SDS 
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Solution III 
5 M potassium acetate  60 ml 
Glacial acetic acid   11.5 ml 
H2O     28.5 ml 
 
2.1.8 Materials for cell culture 
Dulbecco's Modified Eagle's medium (DMEM)   Invitrogen, USA 
Fetal calf serum (FCS)      PAN, Germany 
Opti-MEM        Invitrogen, USA 
100x penicillin-streptomycin solution (P/S)    PAA, Austria 
1x trypsin-EDTA (0.5 g/L trypsin, 0.2 g/L EDTA)   PAA, Austria 
Tissue culture dish                                                                           Greiner, Germany  
Tissue culture flask       NUNC, USA 
Bovine Albumin (BA)      MP Biomedical  
 
2.1.9 Methylcellulose (MC) media, 100 ml (1.75%) 
MEM (10x)  10 ml           
P/S (100x)     1 ml                                      
BA (30%)      1 ml 
NaHCO3 (7.5%)    4 ml 
MC (3%)      58.3 ml 
DEAE Dextran (1%)    1 ml 
dH2O       24.7 ml 
  
2.1.10 Preparation of all kind of buffers 
 
2.1.11 Preparation of TLB buffer  
Tris HCl, pH 7.4   20 mM 
NaCl       137 mM 
Glycerol      10% (v/v) 
Triton X-100     1% (v/v) 
EDTA      2 mM 
Sodium--glycerophosphate  50 mM  
Sodium pyrophosphate   20 mM 
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(Protease inhibitors are added in lysis buffer during making lysates) 
 
2.1.12 Lysis Buffer 
TLB buffer (see TLB buffer)   10 ml 
Pefablock               200 mM 
Aprotinin                                     5 mg/ml  
Leupeptin                                     5 mg/ml 
Sodium orthovanadate                100 mM 
Benzamidine                               1 M 
 
2.1.13 5x SDS-PAGE buffer  
SDS                              5 g 
Tris-base                           30 g 
Glycine                             144 g 
Dissolved in 5 L dH2O. 
 
2.1.14 Transfer buffer (Semi-dry) 
Tris-base    5.8 g  
Glycine     2.9 g 
SDS     0.17 g  
Methanol    200 ml  
Dissolved in 1 L dH2O.  
 
2.1.15 10x TBS (Tris Buffer Saline) 
24.2 g     Tris 
80 g    NaCl 
Adjusted pH to 6.7 with HCl filled to 1 L with dH2O. 1x TBS buffer was used for 
washing membrane and diluting antibody. 
 
2.1.16 1x TBST buffer 
100 ml    10x TBS 
900 ml    dH2O 
0.5 ml    Tween 20 
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2.1.17 blocking buffer 
1g     nonfat dry milk powder 
1g     BSA 
100 ml      1x TBST 
 
2.1.18 SDS-PAGE buffer and gel 
 
0.5 M Tris pH 6.8 (100 ml) 
Tris-base   6.05 g 
dH2O   50 ml  
Adjusted pH to 6.8 with HCl filled to 100 ml with dH2O 
 
1.5 M Tris pH 8.8 (100 ml) 
Tris-base                         18.15 g 
dH2O                               50 ml  
Adjusted pH to 8.8 with HCl filled to 100 ml with dH2O. 
 
Loading buffer (10 ml) 
8 M urea solution            5 ml  
120 mM Tris (pH 7.6)     2 ml  
20% (w/v) SDS               1 ml 
Methanol                         0.5 ml  
Glycerin                          1.5 ml  
Bromphenol blue            0.05 g  
Autoclaved  
 
Resolving gels (10%): 
30% Acrylamide  3.3 ml 
1.5 M Tris pH 8.8 2.5 ml 
10% SDS   100 l 
dH2O   4 ml 
10% APS    50 l 
TEMED    5.5 l 
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Stacking gels 
30% Acrylamide   0.75 ml 
0.5 M Tris pH 6.8 1.25 ml 
10% SDS     50 l 
dH2O   2.9 ml 
10% APS       50 l 
TEMED       3 l 
Rainbow protein size marker                                                    Biorad 
PVDF-Membrane Immobilon-P transfer membrane                Millipore  
STOP SOLUTION                                                                    USB 
Blotting papers 
Kinase Buffer (ICA) 
DAB-substrate (Sigma FAST
TM
) 
FAST
TM
 UREA H2O2) 
True blue 
 
2.1.19 Primer extension sequencing gel (6%) 
Rotiphorese® sequencing gel concentrate                                Roth 
Rotiphorese® sequencing gel buffer concentrate                     Roth 
Rotiphorese® sequencing gel diluents                                      Roth 
 
2.1.20 Materials for cell viability (MTT) test 
Thiazolyl blue tetrazolium bromide powder                             Sigma USA                                
Disposable cell scraper                                                              SARSTEDT 
 
2.2 E. coli strains and cell lines and virus strains 
XL1-Blue                                                                                   Stratagene, Germany 
The following three cell lines were kindly provided by            Prof. Dr S. Pleschka: 
293T (Human embryonic kidney cells)  
MDCK (Madin-Darby canine kidney cells) 
A549 (Human lung epithelial cells) 
A/FPV/Bratislava/79 (H7N7)          Strain collection Giessen 
A/PR/8/34, (H1N1), (PR8) 
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2.3 Agarose gel electrophoresis 
Ethidium bromide 
20000x ethidium bromide stock solution (10 mg/ml ethidium bromide) 
 
6x loading buffer 
0.025% (w/v) bromophenol blue 
30% (v/v) glycerol 
50x TAE 
242 g   Tris base 
57.1 ml   glacial acetic acid 
100 ml   0.5 M EDTA (pH 8.0) 
 
2.4 Monoclonal and polyclonal antibodies 
Anti-P-ERK (E-4) mouse monoclonal IgG            (1:500)   Santa Crutz  
Anti-ERK2 (C-14) mouse monoclonal IgG           (1:1000)  Santa Crutz  
Anti-P-PKC rabbit                                                (1:500)  Santa Crutz  
Anti-PKC mouse                                                   (1:500)                   Santa Crutz  
Anti-P-Tyrosine mouse monoclonal IgG                (1:200)                   Upstate 
HRP conjugated goat anti- mouse IgG                   (1:1000)      Santa Crutz  
HRP conjugated bovine anti-rabbit                         (1:1000)                 Santa Crutz 
HRP conjugated donkey anti-goat                          (1:1000)                 Santa Crutz  
Anti-PB1 goat polyclonal IgG                                (1:200)                   Santa Crutz  
Anti-NS1 goat polyclonal IgG                                (1:500)                   Santa Crutz  
Anti-NS2 goat polyclonal IgG                                                              Santa Crutz  
Anti-NP mouse monoclonal IgG                            (1:200)                   Serotec 
Anti-M1 mouse monoclonal IgG                            (1:500)                   Serotec 
Anti-flu A NP mouse (clone N7C4)                       (1:1000)             L. Stitz  
Anti-flu A NP mouse (clone 1331)                         (1:1000)  Biozol 
Anti-flu A NP (FPV) goat                                       (1:300)  R. G. Webster 
Anti-H7HA mouse monoclonal IgG     Dr. R. Wagner 
FITC conjugated goat anti- mouse IgG                   (1:100)                  Dianova 
FITC conjugated rabbit anti- goat IgG                    (1:100)  Dianova 
FITC conjugated goat anti -rabbit IgG                    (1:100)  Dianova 
Cy5 conjugated sheep anti- mouse IgG                   (1:100)  Dianova 
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Cy5 conjugated rabbit anti -goat IgG                       (1:100)  Dianova 
Cy5 conjugated donkey anti -rabbit IgG                  (1:100)                  Dianova                      
Texas Red conjugated rabbit anti-mouse                  (1:100)   Dianova 
 
2.5 Buffers for Immunoflorescence assay 
100x Ca
2+
/Mg
2+ 
solution  
1 g   MgCl2 
1.32 g   CaCl2 
100 ml               dH2O 
Autoclaved, then filtered with the 0.2 m filter column (SARSTEDT, Germany). 
1x PBS
++
 buffer 
500 ml   1x PBS (autoclaved) 
5 ml   100x Ca
2+
/Mg
2+ 
solution 
10 x PBS 
8 0 g   NaCl 
2 g   KCl 
14.4 g   Na2HPO4 
2.4 g   KH2PO4 
Dissolved in 800 ml of H2O, and then adjust the pH to 7.4 with HCl. Finally add H2O to 
1 L and autoclaved. 
 
Cell fixing buffer (100 ml) 
95 ml   1xPBS++
 
4 ml   Formaldehyde (PFA) 
1 ml   Triton X-100 (t-Octylphenoxypolyethoxyethanol) 
Or only 4% paraformaldehyde (4ml paraformaldehyde dissolved in 96ml 1xPBS++) used 
as a fixing solution when intracellular molecules are prevented for diffusion. 
 
2.6 Mowiol DABCO 
2.4 g   Mowiol 
6 g   Glycerol 
6 ml    dH2O 
Mixed by magnetic stirring over night. Next day 12 ml 0.2 M Tris-HCl (pH 8.5) was 
added and incubated at 50
o
C for 30 min. The viscous mixture was centrifuged at 6000 
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rpm at room temperature for 15 min, and the supernatant was mixed with DABCO (final 
concentration 2.5%). The solution can be stored at -20
o
C for several months. 
  
2.7 Stimulators and Inhibitors 
12-O-tetradecanoyl-phorbol-13-acetate (TPA)                   Sigma 
Calcium channel blocker (Verapamil)                                        Biomol, Germany 
 
2.8 Other materials 
Deoxynucleosidetriphosphate set (dNTP, 100mM)         Promega, USA 
Eppendorf tube              Eppendorf, Germany 
X-ray film             Kodak X-OMAT 
Syringe (5ml, with 25G needle)           Braun, Germany 
Falcon centrifuge tube            Falcon, Germany 
Lipofectamine             Invitrogen, USA 
Lipofectamine 2000             Invitrogen, USA 
Plus Reagent              Invitrogen, USA 
Microtiter plate (96 wells)            Greiner, Germany 
TLC plate             Merck, Germany 
SOC medium              Invitrogen, USA 
 
2.9 Methods 
2.9.1 Maintenance of cell culture 
Mardin-Darby canine kidney cells (MDCK), Human lung epithelial (A549) and 
Human embryonic kidney (HEK) 293T cells were maintained in Dulbecco modified 
Eagles medium (DMEM) containing phenol red as a pH-indicator, supplemented with 
10% heat inactivated fetal calf serum (FCS) and 1x penicillin /streptomycin. The cells 
were incubated at 37°C with 5% CO2 and 95% humidity. They were cultured 
routinely to a 100% confluence and than passaged according to the need. 
2.9.2 Storage and thawing cell cultures  
To freeze confluent cells (75cm
2 
flask), the cells were washed with 1x PBS and 5 ml 
of 1x trypsin-EDTA was added and incubated at 37°C with 5% CO2 for 3-5 min.  
Cells were checked for cell detachment (incubate longer if the cells have not 
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completely detached). After the cells have detached 5 ml fresh medium was added 
and the detached cells were collected and centrifuged at 1,000 rpm (Megafuge 1.0R, 
350 g), 4°C for 5 min.  Supernatant was discarded and pellet was gently resuspended 
in 1 ml freeze medium (complete DMEM media with 10% DMSO) and transferred 
into labelled (cell name, passage No., date and name) cryovials. These vials were set 
into a styropore box and left to freeze gradually in the -80°C freezer. The DMSO 
prevents ice crystal formation and allows the cells to remain intact. After 24 h, frozen 
vials were placed into liquid nitrogen where they can be stored for a longer period of 
time.  
To thaw the cells, they were taken out of the liquid nitrogen and placed immediately 
into 37°C water bath for 5 min. Afterwards cells were resuspended carefully and 
transferred into cell culture flask filled with prewarmed complete DMEM (20 ml for 
A549 and MDCK and 25 ml for 293T cells because 293T cells grow very fast and 
require more energy). On the next day cells will reach a 100% confluency and should 
be passaged for further propagation. 
 
2.9.3 Infection of cells 
A/FPV/Bratislava/79(H7N7) virus strain was used for infection of A549, MDCK and 
293T cells. The virus inoculum was made by diluting the virus stock with certain 
volume of 1x PBS/BA/P/S/Ca
2+
/Mg
2+
 depending on the desired multiplicity of 
infection (MOI) used for experiment. A549, MDCK and 293T cells were seeded with 
2 ml volume cell suspension into 3.5 cm dishes and grown to confluency by 
incubating at 37°C with 5% CO2
 
overnight or at least 16-18 h.  The cells were washed 
with 1x PBS++, and then 100 l of viral inoculum (virus stock diluted in 1x 
PBS/BA/P/S/Ca
++
/Mg
++
) was laid on the cells by creating bubbles or foam in the 
centre of the dish to ensure a consistent virus distribution. The cells were incubated at 
room temperature for 1h. There after inoculum was aspirated and 2 ml of 
DMEM/BA/P/S was added. Cells were then further incubated at 37°C with 5% CO2 as 
needed/indicated.  
The calculation of m.o.i. is done as follows: 
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2.9.4 Preparation of cell lysates for Western blot analysis 
At indicated time post stimulation or infection cells, were washed with cold 1x 
PBS++. Thereafter-another 1 ml of cold 1x PBS++ was added to the cells. Then with 
the help of cell scraper the cells were scraped off and transferred into eppendorf cups. 
Scraped cells were collected in a falcon and centrifuged at 13,000 rpm (Biofuge 13, 
25,000 g) for 1 min. Supernatant was discarded and cell pellet was resuspended in 75 
l lysis buffer. The lysis was done by incubating cells for 20-30 min on ice with 
vortexing at every 5 min interval. The lysed cells were centrifuged at 13,000 rpm 
(Biofuge 13, 25,000 g), at 4°C for 15 min. The supernatant, which contains desired 
proteins, was finally transferred into new eppendorf and was either used or stored at -
70°C. 
 
2.9.5 Western blotting (Semi-dry) 
2.9.5.1 Measurement of protein concentration (Bio-Rad protein assay) 
The Bio-Rad Protein Assay is based on the observation that when Coomasie Brilliant 
Blue G250 binds to the protein the absorbency maximum shifts from 450 nm to 595 
nm [250]. 5 l of cell lysate was added into diluted Bio-Rad Dye Reagent (1:4 
dilution of Dye Reagent concentrate in ddH2O) and mixed well. After a period of 10 
min, the protein content was determined by measuring the absorption at wavelength 
595 versus reagent blank (containing the lysis buffer only). This was done to apply an 
equal protein amount of all samples onto the SDS-PAGE gel. 
 
2.9.5.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The electrophoresis apparatus was assembled according to manufacturer's (Bio-Rad) 
instruction, and the resolving gel was poured in between the two glass plates. Leave a 
space about 1 cm plus the length of the teeth of the comb. Isopropanol, 100% ethanol 
or ddH2O was added to the surface of the gel to apply the same distribution along the 
1000 l 
Virus titer (PFU/ml)   MOI  x  cell amount in the culture 
X l virus 
= 
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gel surface. After the resolving gel was polymerized, isopropanol was removed and 
the stacking gel was poured on top of the resolving gel. Insert the comb and let the gel 
polymerise. 75 l of sample (after determining the protein concentration) with 35 l 
laemlli buffer containing 10% -mercaptoethanol to reduce disulphide bonds were 
incubated for 5 min at 95
o
C and cooled on ice for 1 min, then shortly centrifuged and 
the calculated amount was loaded into wells of gel. Rainbow protein marker (2 l 
marker + 8 l laemlli buffer) or odyssey machine specific protein marker was loaded 
as control. Before running, 1x SDS-PAGE running buffer was added to the chamber, 
a cover was placed over the gel chamber. Gels should be run at about 20 V/cm gel 
length. The negatively charged SDS-proteins complexes migrate in the direction of 
the anode at the bottom of the gel. Small proteins move rapidly through the gel, 
whereas large ones stay at the top. Proteins that differ in mass by about 2% can be 
distinguished with this method. The electrophoretic mobility of many proteins in 
SDS-polyacrylamide gels is proportional to the logarithm of their mass. 
 
2.9.5.3 Transfer membrane in "Semi-dry" electroblotter  
After the cell extracts were subjected to SDS-PAGE, the proteins were transferred by 
electroblotting onto a PVDF-Membrane, which was incubated before in 100% 
Methanol for 2-3 min, and washed three times (5 min each) in ddH2O, then 
equilibrated in the transfer buffer for 2-3 min. On the layer of 2 blotting papers the 
PVDF-Membrane was laid. The polyacrylamide gel and again 2 blotting papers were 
then placed on the PVDF-Membrane, making a "sandwich" (without any bubbles), 
and laid in "Semi-dry" Electroblotter (Scheicher & Schuell, Germany). The current 
was set to 0.8 mA/cm
2
 for 1 blot for 90 min for transfer.  
 
2.9.5.4 Immunodetection of proteins on PVDF-Membrane 
After transferring the proteins, the PVDF-Membrane was washed for 5 min in 1 x 
TBST buffer, then the membrane was blocked in blocking buffer (1% milk powder + 
1% BSA in 1x TBST) for 2 h at room temperature or overnight at 4°C on flip flop 
shaker (for best result). There after the membrane was washed for 5 min in 1x TBST 
buffer, then incubated with the primary antibody for 1 h at room temperature or 4
o
C 
on flip flop shaker or overnight at 4
o
C on flip flop shaker depending on the conditions 
Materials and Methods                                                                                                    43
of antibodies binding with proteins prescribed by company. After washing three times 
(5 min each) in 1 x TBST buffer, the membrane was incubated with the secondary 
antibody solution for 1 h at room temperature or 4
0
C on flip flop shaker. 
 
2.9.5.5 Enhanced Chemiluminescence (ECL) reaction 
As mentioned above the membrane was washed three times (5 min each) in 1x TBST 
buffer and once in 1x TBS, then incubated in ECL (enhanced chemiluminescence, 1:1 
ratio of reagent 1 and 2 i.e. 4 + 4 = 8 ml/blot or according to manufacture 
(Amersham) protocol) for 1 min in a plastic tray. After 1 min incubation in ECL 
solution, membrane was transferred between a glass plate and a clear plastic 
membrane and was laid into a photo cassette, and then a light sensitive film (Bio Max 
Film MR1, Kodak) was placed on top of the membrane and exposed for 1.5-5 min or 
depending on the desired intensity of bands. The film was then developed (Protec, 
Processor-Technology, Germany). 
 
2.9.5.6 Striping of bound antibodies from the PVDF Membrane 
In order to detect the ERK2 protein (as a loading control), the attached antibody was 
striped from membrane by incubating with a 1:10 diluted strong stripping solution 
(Re-Blot Plus Western Blot Recycling Kit, Chemicon) for 45-60 min at room 
temperature or Roth striping solution 20-25 ml/blot for 1-2 h at 37
o
C. After washing 
with 1x TBST buffer for 5 min, the membrane was incubated in blocking buffer for 2 
h at room temperature or 4
o
C on flip flop shaker or overnight at 4
o
C on flip flop 
shaker. Then it was washed for 5 min in 1x TBST buffer and incubated with the anti-
ERK2 mouse monoclonal antibody solution for 1 h at room temperature or 4
o
C 
followed by secondary antibodies incubation for 1 h. Subsequently the membrane was 
washed three times in 1x TBST buffer and washed once in 1x TBS, then incubated for 
1 min in ECL solution and proceeded as mentioned above. The bands were then 
detected by ECL. 
2.9.5.7 Quantification of protein bands 
Protein bands exposed on the film were scanned (Cano scan LiDE 30/N1240U) at 800 
dpi and the picture was saved in grey scales as TIFF file. The intensity of protein 
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bands was densitometrically determined by means of PC-BAS software (Fuji film). 
To determine the relative amount of the protein of interest protein bands were 
quantified and normalized in relation to the loaded ERK2 protein. The lowest value of 
the loading control (PKC or ERK2) was set to one and divided by the value of the 
other bands of the loading control to get a factor for each corresponding band of the 
protein of interest and this factor was multiplied with the value of the band of the 
protein of interest. In case of viral proteins detection, the lowest ERK2 value was also 
set to one and divided by the other ERK2 values to get a factor that was multiplied 
with the value of the viral proteins. This calculation was done to normalize the 
amount of P-PKC, P-ERK and viral proteins by the amount of ERK2 protein loaded. 
 
2.9.6 Detection of influenza A viral proteins 
A549 cells were grown to confluence in T75 flask. The following day, cells were 
washed with 1x PBS and trypsinized in 5 ml 1x Trypsin by incubating at 37ºC in 5% 
CO2 incubator. After complete detachment of the cells from the wall of the flask, 5 ml 
complete DMEM (DMEM /10%FCS/P/S) was added into flask and cells were mixed 
properly by pipetting in and out with glass pipette to make a clear cell suspension. In 
these 10 ml cell suspension 38 ml complete DMEM media was added to make the 
total cell suspension about 48 ml. From this cell suspension 3.5 cm dishes were 
seeded by distributing 2 ml cell suspension in each dish and incubated at 37ºC in 5% 
CO2 incubator for overnight. Next following day after confluency (90-100%), cells 
were washed with 1x PBS++
 
and infected at (MOI=1) with 100μl virus dilution in 
1xPBS++/BA/P/S/Ca
2+
/Mg
2+
 by creating a bubble in the centre of the dish to hold the 
liquid and the dish was incubated at room temperature for 1h. 1h post incubation virus 
dilution in the dishes were  aspirated and 2 ml DMEM/BA/P/S media was added in 
each dish and incubated at 37ºC in 5% CO2 incubator for the indicated time points (4, 
6, 8 and 10 h).  After 2 h p.i cells were treated with 100 μM Verapamil by adding 20 
μl Verapamil (from the stock 10 mM) solution in 1 ml media taken out from the 
respective dishes and was mixed properly and again transferring back to the same dish 
and incubated at 37ºC in 5% CO2 incubator. At every indicated time points dishes 
were taken out from the incubator and washed with ice-cold 1x PBS++ or 1x PBS. 
Further in 1 ml ice-cold 1x PBS++ or 1x PBS, cells were scraped (by disposable cell 
scraper, SARSTEDT) and transferred into new eppendorf. Cells were centrifuged at 
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13000 rpm for 30-60 seconds and pellets were dissolved in 75 μl Tris lysis buffer 
(TLB) containing protease inhibitors. Cell lysates were incubated at ice for 20 min 
and at every 5 min interval cell lysates were vortexed. After 20 minutes incubation at 
ice cell lysates were centrifuged at 13000 rpm for 15 min at 4ºC. The supernatant 
which is a lysate is transferred into new eppendorf and stored at -20ºC or -70ºC or 
until required for the use. 
 
2.9.6.1 Western blot analysis of viral proteins 
Calculated protein amount was loaded onto 10% Polyacrylamide gel. After clear 
separation of proteins and the loading dye about to touch the bottom, the gel was 
taken out from the western blot chamber and transferred on nitrocellulose membrane 
for 90 min (48 mA current/gel).  Blot was washed twice with 1x TBST and then 
blocked in blocking buffer (1% milk powder +1% BSA) either for 2 h or overnight 
(4ºC on flip flop shaker in plastic bag). Later blots were incubated overnight with 
primary antibodies (anti-NP mouse, 1:200, anti-M1 mouse 1:500, anti-PB1 rabbit 
1:200 and, anti-NS1 rabbit 1:500 in blocking buffer) at 4ºC on flip flop shaker in 
plastic bag. Blots were washed thrice in 1x TBST washing buffer and then incubated 
with secondary antibodies (HRP conjugated anti-mouse and anti-rabbit) for 1 h at 4ºC 
on flip flop shaker in plastic bag. The bands were then detected by ECL. 
In order to detect the ERK2 protein as the loading control, the attached antibody was 
striped from the membrane and blocked in blocking solution. The membrane was 
incubated with the primary mouse anti-ERK2 monoclonal antibody solution for 1 h at 
room temperature followed by 1 h secondary antibodies incubation. Subsequently the 
membrane was washed three times in 1x TBST buffer and washed once in 1x TBS, 
then incubated for 1 min in ECL solution and proceeded as described above. Finally 
the bands were quantified and the values were normalized to the loading control. 
2.9.7 Immuncomplex kinase assay (ICA) 
The kinase activity can be measured in vitro by radioactivity of (32P) ATP labelled 
substrate of the kinase. To determine PKC and ERK activity, A549-cells were 
infected with FPV (MOI=1) and either left untreated or were treated with Verapamil 
(100M/ml, 2 h p.i.), cell lysates were made at 8 h p.i  and 10 h p.i. and used for ICA, 
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using myelin basic protein (MBP) as substrate indicating kinase-activity. Loading was 
controlled with anti PKC and ERK-specific mAbs in WB-analysis. 
 After infection and Verapamil treatment at indicated time points, cells were washed 
with cold 1x PBS++. Thereafter another 1 ml of cold 1x PBS++ was added to the 
cells, then they were scraped off and transferred into eppendorf cups. These were then 
centrifuged at 13,000 rpm (Biofuge 13, 25,000 g) for 1 min and the cell pellet was 
resuspended in 75 l lysis buffer. The lysis was done by incubating cells for 20-30 
min on ice and intermittent vortexing every 5 min interval. The lysed cells were 
centrifuged at 13,000 rpm (Biofuge 13, 25,000 g), 4ºC for 15 min. The supernatant 
was finally transferred into new eppendorf cups and stored at -70ºC till required. The 
immunoprecipitation was performed by incubating the 12CA5 anti HA monoclonal 
antibody and protein A agarose for 2 h at 4ºC. Immunoprecipitated kinase was 
washed twice first with TLB buffer and then with Kinase buffer. 5Ci (32P) ATP, 2-
5 g of substrate (2mg/ml dephosphorylated myelin basic protein (MBP) in 20mM 
MOPS, pH 7.2, 25mM -glycerophosphate, 5mM EGTA, 1mM sodium 
orthovanadate, 1mM dithiothreitol; Upstate cell signalling solution) was added, 0.1 
mM ATP, and 20 l Kinase buffer were added. The mixture was incubated at 30°C 
for 30 min essentially as described [251]. The reaction is then stopped by adding 
SDS-loading buffer and incubated at 95°C for 5 min. Immune complexes were used 
for in vitro kinase assays with purified MBP as substrate for ERK as previously 
described [186]. The proteins are separated by SDS-PAGE and then blotted onto 
nitro-cellulose membranes. After Western blot proteins were detected by a BAS 2000 
Bio Imaging Analyzer (Fuji film) and autoradiography. Quantification of specific 
bands was done with the PC-BAS software package. Western blot analysis with the 
anti ERK2 or 12CA5 anti HA monoclonal antibodies was performed to monitor equal 
loading of kinases. This assay was performed in collaboration with Centre for 
Molecular Biology (ZMBE), Münster. 
 
2.9.8 Cell viability test (MTT Assay) 
Verapamil is a calcium channel blocker and indirect inhibitor of PKC. I used 100 
M/ml Verapamil in my studies. In order to determine whether this concentration has 
any detrimental affect on cell viability, the MTT Formazan-assay was performed. 
This assay measures the activity of mitochondrial dehydrogenase in the living cells. 3-
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(4, 5-dimethylthiazole-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) is taken by the 
cells and reacts with NADH, which is reduced to NAD. This reaction produces blue 
formazan crystals in living cells. 
A549 cells were seeded in 96 well cell culture plates (200 l/well from 10ml cell 
suspension diluted in 45 ml complete 1x DMEM and grown overnight at 37˚C with 
5% CO2 so that they were confluent on the next day. Confluent cells were either left 
untreated or were treated with Verapamil (100M mixed in DMEM) and incubated 
for an additional 4, 6, 8 and 10 h at 37˚C with 5% CO2 incubator. Then the medium 
was replaced with 200 l of complete DMEM media and incubated for 1 hour to 
allow cell proliferation. 7 l of 5 mg/ml MTT stock solution was diluted in 193 l 
complete DMEM media (175 g/ml final concentrations) and added into each well 
after aspirating the old media. Cells were incubated further for 90 min and 
subsequently fixed with 4% paraformaldehyde (PFA, in 1x PBS) at room temperature 
for 30 min. The fixing solution was aspirated and the plates were air dried under the 
hood for 10-15 min. The tetrazolium crystal was dissolved by adding 200 l of 
isopropanol to each well and shaking them by placing the plates on 96-well plate 
shaker for 10 min. The plates were analyzed photometrically at 550 nm excitation in 
an enzyme-linked immunosorbent assay (ELISA) reader. 
 
 
2.9.9 Analysis of infectious virus titres 
2.9.9.1 Immunohistochemistry (Focus forming units, FFU) 
Immunohistochemistry is the localization of antigens or proteins in tissue sections by 
the use of labeled antibodies as specific reagents through antigen-antibody 
interactions that are visualized by a marker such as fluorescent dye, enzyme, or 
colloidal gold. 
 
Virus dilution was made in the 96 well U-bottom microtiter plates. First 180 l of 
1xPBS++/BA/P/S/Ca
2+
/Mg
2+
 was pipetted into each well of the first row and then 20 
l of the virus stock or virus supernatant collected from A549 infected cells was 
added into the wells of the first row. The virus dilution (200 l) was mixed by 
pipetting in and out and 20 l of it was transferred into subsequent wells of the second 
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row. The same steps were repeated up to the last row to get a 10
-1
 to 10
-8
 dilution 
series. 
 
The MDCK cells were seeded in 96 well plate (10 ml cell suspension + 45ml DMEM 
complete media = 55 ml, distribute 150 l/well) and grown over night at 37ºC with 
5% CO2 so that they reach 90-100% confluency on the day of infection. The next day, 
cells were washed once with 200 μl 1x PBS++, then infected with 50 l of various 
virus dilutions and incubated at room temperature for 1 h. Virus inoculum was 
aspirated and 150 l or 100 l methylcellulose media was added into each well. The 
plate was placed at 37°C with 5% CO2 for 30h in case of FPV and 48 h in case of 
other viruses like PR8. After the incubation time, methylcellulose media was removed 
by aspiration. Cells were washed twice with 1x PBS++ and fixed as well as 
permeabilized with 100 l of 4% PFA/1% TritonX-100 in 1x PBS++ for 25 min at 
room temperature or overnight at 4°C. Later cells were washed three times with 1x 
PBS++/0.05% Tween20 and incubated with 50 l of primary antibody (anti NP-mAb, 
1:1000 diluted in 1x PBS++/3% BSA) for 45 min or 1 h at room temperature. After 
aspirating the primary antibody dilution, cells were washed three times with 
PBS++/0.05% Tween20, followed by incubation with secondary antibody  (Horse 
Radish Peroxidase (HRP)-conjugated anti mouse, 1:1000 diluted in PBS++/3% BSA) 
for 45 min at room temperature. Cells were washed twice with 1x PBS++/0.05% 
Tween20 and 100 l DAB-substrate (first, one silver pill Sigma FASTTM DAB) was 
dissolved in 15 ml 1x PBS followed by dissolving one golden pill (Sigma FAST
TM
 
UREA H2O2) or True blue was added into each well and incubated at room 
temperature for 5-10 min. When brown or blue stained foci’s respectively were 
observed under the microscope the cells were washed with normal water to remove 
the rest of salts and air dried at room temperature until the next procedure of analysis. 
After scanning and counting of foci’s, the viral titre was determined as follows: 
 
FFU/ml = number of foci’s x volume factor x dilution factor 
Volume factor: FFU (Foci forming unit) is related to 1 ml. If a dish was infected with 
50 l viral dilution solution, the factor is 20.  
Materials and Methods                                                                                                    49
2.9.10 Immunoflorescence assay (IFA)/Laser scanning confocal microscopy 
The confluent cells in a culture flasks were washed with 1x PBS and trypsinized by 
adding 5 ml 1x trypsin-EDTA and incubated at 37ºC with 5% CO2 incubator for 5-10 
minutes or until cells were completely detached. 5ml complete DMEM media was 
added in the trypsinized cells and resuspended by pipetting in and out. These 10 ml 
cell suspensions were resuspended in 45 ml complete DMEM media and seeded 2 ml 
in each 3.5 cm dish containing 2x sterile glass coverslips (12 mm) and incubated at 
37ºC with 5% CO2. On the next day, the cells were confluent. Cells were washed with 
1xPBS++ and infected with IV (MOI=1 or 5) or treated with TPA (100ng/ml) and 
infected cells were treated with Verapamil at non toxic concentration (100M). 
Depending on the purpose of the experiment, the growth medium was removed from 
the culture dish, and the cells were washed once with 1x PBS++, then the cells were 
fixed with 1 ml 4% PFA in 1x PBS++ without or with 1% Triton X-100 (depending 
on the aim of the experiment) for 30 min at room temperature or over night at 4ºC. 
After fixation, cells were washed twice with 1x PBS
++
 and subsequently incubated 
with 25 l of the primary antibody (1:200 dilution in 1x PBS++/3% BSA) for each 
coverslip for 1 h at room temperature or 37ºC with 5% CO2 incubator. Afterwards 
cells were washed twice as mentioned above, then incubated with 25 l of the either, 
FITC, CY5, or Texas red conjugated secondary antibodies (1:100 dilution in 
PBS++/3% BSA) for 1 h at room temperature under dark conditions. Then the cells 
were washed twice as mentioned above, and once with ddH2O. The glass coverslip 
was fixed on the glass carrier with Mowiol, and hardened overnight by incubating at 
4ºC. The analysis was done on next day with a confocal laser scanning microscope.  
 
2.9.11 Preparation of plasmid DNA 
Plasmid DNA mini preparation was normally done according to the following 
protocol: a single bacterial colony or 5 μl glycerol stocks was transferred into 5 ml of 
LB medium containing 100 g/l ampicillin in a loosely capped 15 ml glass tube. The 
tube was incubated overnight at 37ºC with vigorous shaking. 1.5 ml of culture was 
poured into a microfuge tube and centrifuged at 6000 rpm (Biofuge 13, 5,000 g) for 4 
min at 4ºC in a microfuge. The medium was removed by aspiration, leaving the 
bacterial pellet as dry as possible. The pellet was resuspended in 100 μl of solution I 
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by vigorous vortexing, until the pellet was dispersed. Then 200 μl of prepared 
solution II was added, the contents were mixed by inverting the tube rapidly six times 
and left at room temperature for max 5 min. 150 μl ice-cold solution III was 
subsequently added, the tube was vortexed gently for 10 seconds and stored on ice for 
10 min. The tube was centrifuged at 13,000 rpm (Biofuge 13, 25,000 g) for 10 min at 
4ºC in a microfuge and the supernatant was transferred to a new tube. The DNA was 
precipitated by adding 250 l of isopropanol at room temperature and the contents 
were mixed by vigorously vortexing. The tube was centrifuged at 13,000 rpm 
(Biofuge 13, 25,000 g) for 15 min at 4ºC in a microfuge. After centrifugation the 
supernatant was removed by gentle aspiration, and then the pellet was rinsed with 500 
μl of chilled 70% ethanol and centrifuged for 5 min at 13,000 rpm (Biofuge 13, 25000 
g). The supernatant was removed and the pellet of DNA was air-dried for 10 min at 
room temperature or exposing to heated lamp. Then the DNA was redissolved in 100 
μl TE (pH 8.0) containing DNAase-free pancreatic RNAase (20 g/ml) or ddH20. 
 
Plasmid DNA maxi preparation was preformed using QIA prep plasmid midi or maxi 
kit. The 100 μl (glycerol stock) cultures of bacteria containing plasmids were grown 
in 100 ml of LB media overnight in 37ºC incubator with shaking at 200 rpm. The 
bacteria were collected by centrifuging the overnight culture at 6,000 rpm (Beckman 
JA14, 7,500 g) and 4ºC for 15 min. There after the bacterial pellet was resuspended in 
10 ml of buffer P1 and 10 ml buffer P2 was added. The whole mixture was mixed 
gently and incubated at room temperature for 5 min. 10 ml of chilled buffer P3 was 
added, mixed immediately and incubated on ice for 20 min. The mixture was 
centrifuged at 4,000 rpm (Megafuge 1.0R, 5,400 g) for 30 min at 4ºC. The 
supernatant was applied to an equilibrated QIAGEN-tip 500 and allowed to enter the 
resin by gravity flow. The QIAGEN-tip was washed twice with 30 ml buffer QC. 
DNA was eluted with 15 ml buffer QF. The DNA is precipitated by adding 0.7 
volumes (10.5 ml) of isopropanol and centrifugation at 12,000 rpm (Beckman JA20, 
21,000 g) for 30 min at 4ºC. The resulting pellet was washed twice with 70% ethanol 
and air-dried at room temperature. The pellet is then carefully resuspended in certain 
volume of TE buffer depending on the size of DNA pellet. The concentration of 
plasmid DNA was measured photometrically and adjusted to 1 g/l. The plasmid 
DNA can be stored at 4ºC for a short time only or at -20°C over a longer period. 
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2.9.11.1 Measurement of plasmid DNA concentration 
The DNA concentration is determined by using a DNA photometer (GeneQuant II, 
Pharmacia Biotech) at wavelength of 260 nm. The absorption of 1 at 260 nm 
corresponds to a concentration of 50 g/ml double stranded DNA. First of all an 
appropriate DNA dilution (normally 1:100 in H20 or TE buffer) was made, 
transferred into a quartz crystal cuvette and placed into the photometer, which has 
been calibrated before to the solvent (either H2O or TE buffer). The desired OD 
should lie between 0.2 and 0.4 to ensure correct measurement. 
2.9.11.2 Restriction endonuclease digestion 
Digestion of DNA with restriction endonuclease was performed by pipetting DNA 
sample, 10x restriction buffer, restriction enzyme, and distilled and deionised water 
(ddH2O) in a 1.5 ml eppendorf tube. The reaction mixture was incubated at the 
recommended temperature (usually at 37ºC). Normally 1-5 U of restriction enzyme 
was used to digest 1 μg DNA. Restriction endonucleases were inactivated by heating 
65ºC for 15 min. 
2.9.11.3 Agarose gel electrophoresis 
1% agarose gels were routinely used for analyzing DNA. The agarose was melted in 
1x TAE buffer using a microwave oven, and cooled to about 55ºC or pleasant warm 
to touch. Before the gel was poured into a casting platform, ethidium bromide (8 l 
(stock 10 mg/ml) per 100 ml of dissolved 1% agarose) was added. DNA samples were 
mixed with appropriate amount of 6x DNA loading buffer before loading into the 
wells. Normally, the gel was run at 100-120 V and 300-400 mA. DNA was visualized 
by placing gel on a UV transilluminator and picture was captured directly by a photo 
system. 
 
2.9.12 DNA-transfection of eukaryotic cell cultures 
2.9.12.1 Transfection of adherent 293T cells 
293T cells were split 1:2 into a new T-75 flask one day prior to transfection to 
promote cell growth. The next day, 2 ml cell suspension was seeded in 3.5 cm dishes 
in such a way (1:3 dilutions) that cells reach up to approximately 90% confluency 
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over night for the transfection. To transfect the cells 7g DNA (2:1:1:1:2 ratio of 
pPOL1-CAT-RT, pHMG-PB1, pHMG-PB2, pHMG-PA and pHMG-NP plasmid 
DNA of the stock 1 g/l) was diluted in 90 l 1x DMEM (without serum and 
antibiotics) in a tube A (5 ml polystyrene Round-Bottom Tube, Falcon), then 10 l 
Plus Reagent was added into the mixture and gently mixed by pipetting up and down 
and incubated at room temperature for 15 min. Just before completion of 15 min 
incubation of tube A, 7 l Lipofectamine Reagent was diluted in 93 l 1x DMEM 
(without serum and antibiotics) in another tube B (5 ml polystyrene Round-Bottom 
Tube, Falcon) and mixed by pipetting up and down. The diluted Lipofectamine 
Reagent (7 + 93 = 100 l) in tube B was added to the tube A containing pre-
complexed DNA and Plus Reagent in 1x DMEM without serum and antibiotics (7 + 
10 + 90 = 107 l). Then the mixture A and B was mixed gently and incubated for 30 
min at room temperature. While complexes were forming, the media in each dishes 
was replaced with 800 l 1x DMEM (without serum and antibiotics). The DNA-Plus-
Lipofectamine Reagent in 1x DMEM without serum and antibiotics complexes (total 
107+100= 207 l volume) were added drop wise into the dish containing fresh 
medium. The dropwise added complexes were mixed with the medium by gentle 
shaking the dishes and incubated at 37
o
C at 5% CO2 for minimum 6 h. Thereafter, the 
media containing DNA-Plus-Lipofectamine Reagent in 1x DMEM (without serum 
and antibiotics) complexes was removed and replaced with 2 ml of complete DMEM 
media. The cells were further incubated at 37
o
C at 5% CO2 for 24-48 h. 
  
2.9.12.2 Transfection of suspended MDCK cells 
The day before transfection, MDCK cells were split 1:2 into a new flask to promote 
cell growth. On the day of transfection, confluent cells in 75 cm
2
 culture flask were 
washed with 1x PBS, trypsinized by 5 ml Accutase I and incubated at 37°C for 15 
min. During incubation time, DNA and Lipofectamine 2000 (L2000) mix were 
prepared as follows: 4 g DNA was diluted in 50 l of OPTI-MEM reduced serum 
medium and mixed gently in a 5 ml polystyrene round-bottom tube. L2000 was mixed 
gently before using, than 12 l of L2000 was diluted in 238 l of OPTI-MEM in 
another 5 ml polystyrene round-bottom tube, mixed gently and incubated not longer 
than 5 min at room temperature. The diluted L2000 was added to the tube containing 
the diluted DNA, then mixed gently and incubated for 20 min or longer at room 
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temperature to allow forming of the DNA-L2000 complexes. After cell trypsinization, 
5 ml medium without antibiotics (DMEM with 10% FCS) was added into the flask, 
the mixture was transferred into a 15 ml Falcon centrifuge tube and subsequently 
centrifuged at 1,000 rpm (Megafuge 1.0R, 350 g) for 5 min. The supernatant was 
removed by aspiration, and then the cell pellet was resuspended by adding 7 ml 
medium (DMEM with 10% FCS). 700 l of cell suspension was mixed with 300 l of 
DNA-L2000 complexes and reseeded onto 3.5 cm dishes. The cells were incubated at 
37
o
C with 5% CO2 for 6 h, and then 1 ml of media (DMEM with 10% FCS) was 
added. 24 h after transfection the media containing DNA-L2000 complexes was 
replaced with 2 ml of complete DMEM media. 
 
2.9.13 Primer Extension 
The primer extension reaction was used to quantify the amount of viral cRNA, vRNA, 
and mRNA. One uses a radiolabeled primer that is complementary to a region towards 
the 5' end of the transcript, to generate a single stranded DNA molecule towards the 5' 
end of the RNA. The size of the labeled single-stranded DNA is then determined on a 
6% sequencing gel. I used total RNA of transfected 293T cells.  
 
2.9.13.1 Transfection and RNA Isolation 
Two different approaches were used to test the effect of Verapamil on viral 
polymerase for the production level of cRNA, mRNA and vRNA either in 5 plasmid 
based replication system (mini genome replication system) or pPOL1-CAT-RT + 
virus replication system. 
293T cells were grown overnight or until confluency in 3.5 cm dishes. Confluent cells 
were washed with 1x PBS and replaced with 800 μl fresh serum and antibiotic 
(pen/strep) free media. In the case of “5 plasmid based” replication system, pPOL1-
CAT-RT, pHMG-PB1, pHMG-PB2, pHMG-PA and pHMG-NP plasmid were diluted 
in the ratio (2:1:1:1:2 ratio of pPOL1-CAT-RT, pHMG-PB1, pHMG-PB2, pHMG-PA 
and pHMG-NP plasmid DNA of the stock 1g/l) and transfected using 
lipofectamine and plus reagent. In the case of “5 plasmid based” replication system, 
24 h.p.t cells were directly treated with Verapamil as indicated and incubated at 37
0
C 
at 5% CO2 incubator for 8 h. 
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In the case of “pPOL1-CAT-RT+ virus” replication system, 293T cells were 
transfected with only 2 μl ((2μg) from the stock of 1μg/μl plasmid DNA and after 24 
h p.t. (hours post transfection) cells were infected with FPV (MOI=1). After 2 h p.i. 
cells were treated with Verapamil (100μM/ml) and incubated at 37˚C at 5% CO2 
incubator for 8h.  
After 32 h.p.t and treatment in both the case media from cells was replaced by 1 ml 
trizol and incubated at room temperature in the laminar hood for 15 min. After 15 min 
cells with trizol are pipetted in and out several times until the trizole cells mix 
becomes liquid. These trizole treated samples are transferred in a new RNAase free 
eppendof and incubated at -70
0
C for overnight or it is used directly for RNA isolation. 
 
2.9.13.2 RNA isolation 
To each eppendorf tube 200 μl of chloroform was added and mixed properly and 
incubate for 5 min at room temperature with occasional shaking. Later the tubes were 
centrifuged for 20 min at 4
0
C at 13000 rpm. The upper phase (app. 0.6ml) was 
transferred later into fresh RNAase free eppendorf. 0.5 ml isopropanol was added to 
this upper phase supernatant and mixed properly and incubated at room temperature 
for 10 min. Centrifuge at 13000 rpm for 20 min at 4
0
C. The supernatant is removed 
carefully and 1 ml of freshly made 70% ethanol was added to the pellet and 
centrifuged at 13000 rpm for 5-10 min at 4
0
C. Without dislodging the pellet, alcohol 
content was discarded and pellet was air dried for 5-10 min and dissolved in 50 μl 
RNAase free (DEPC) H20 and used directly for the experiment or frozen at -70
0
C. 
 
2.9.13.3 DNA marker labeling 
Two types of DNA marker (Bioline and DNA hyper ladder IV) are labeled with 32P. 
Mixture of 13.5 μl autoclaved dH20, 5 μl each of DNA ladder marker, 2.5 μl 10x PNK 
buffer (Roche), 3μl 32P (30 co of the stock of 10μC/ μl) and 1 μl T4 polynucleotide 
kinase (PNK, 10U/ μl) were properly mixed by pipetting in and out and incubated at 
37
0
C (PCR machine) for 1h. After 1h incubation reaction was stopped by adding 5 μl 
STOP SOLUTION (USB). 5-10 μl were loaded onto the 6% seq. gel. 
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2.9.13.4 Primer labeling 
CAT-89: 5’ATGTTCTTTACGATGCGATTGGG3’ 
CAT-2:   5’CGCAAGGCGACAAG GTGCTGA3’ 
5S-rRNA: 5’TCCCAGGCGGTCTCCCATCC3’ 
Two types of primers (CAT-89 and CAT-2) are used for the detection of cRNA, 
mRNA and vRNA. CAT-89 primer anneals with positive sense cRNA and mRNA 
but the product length of the two (cRNA -89 nucleotides an mRNA -106 nucleotides) 
differs by a factor of 17 nucleotide. mRNA is longer than cRNA due to CAP structure 
at 5’end and polyadenylation signal at 3’end. CAT-2 primer anneals with negative 
sense vRNA and gives the product size of 158 nucleotides. 5S-rRNA primer is used 
to anneal internal loading control of 5S-rRNA and gives 100 nucleotide length 
products. 
Each primer stock is 100 pmol/μl. Before labeling these primers (each primer) is 
diluted in DEPC water to a working concentration of 10 pmol/ μl from the stock. 
 
2.9.13.5 Primer labeling reaction 
Primer                                                                  3 μl 
DEPC H20                                                           2 μl 
10xPNK buffer (Roche)                                      1 μl 
32P- ATP (30μCi)                                               3 μl 
T4 polynucleotide kinase (PNK, 10U/ μl)           1 μl  
Mixed well and incubated at 37
0
C for 1h in PCR thermoblock. After 1h incubation, 
samples are taken out of the block and 40 μl of DEPC water is added into each 
eppendorf.  This 50 μl mixture is transferred into new 1.5 ml RNAase-free eppendorf 
and further 450 μl PN-buffer (Qiagen Nucleotide removal kit) is added, mixed well 
and placed over the Qiagen Nucleotide removal column with the help of a pipette. 
The column is spun for 1 min at 6000 rpm and the collection is discarded. The column 
is washed 2 times with 500 μl PE-buffer. Further spun down for 1 min at 6000 rpm 
and the collection is discarded followed by one more time spinning down for one 
minute at 13000 rpm to remove residual alcohol content in the column. Fresh 1.5 ml 
RNAase free eppendorfs are labeled clearly and the column is placed onto it. 40 μl 
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EB-buffer or DEPC H20 is added on the column and incubated for 2 min at room 
temperature. Finally the tube is centrifuged for 1 min at 13000 rpm and the eluate (40 
μl) is collected in the eppendorf. This can be stored at -200C in isotope room. 
 
2.9.13.6 Primer Extension (Reverse Transcription) 
Primer-Mix : Before RT (cDNA preparation), mix the following primers as 
follows according to the no. of samples and always make surplus than the need. 
No.of samples x1 x12 x14 x16 
Labeled Cat 2 0,25 l 3 l 3,5 l 4 l 
Labeled Cat 89 0,25 l 3 l 3,5 l 4 l 
DPEC H2O 0,5 l 6 l 7 l 8 l 
 
No.of samples x1 x12 x14 x16 
Labeled 5srRNA 0,25 l 3 l 3,5 l 4 l 
DPEC H2O 0,75 l 9 l 10,5 l 12l 
 
Note: 5s rRNA  was diluted 1:100 before use 
200 l PCR eppendorfs were labeled. For 1 sample reaction, 10 l trizol-purified 
RNA was mixed with 1 l primer mix and placed in PCR machine. Water control was 
also used for this experiment and instead of 10 l RNA, 10 l water was mixed with 1 
l primer mix. The PCR reaction was run at 95°C for 3 min, 50°C for 92 min and 
70°C for 3 min, 4°C ~ . In the mean time prepare Superscript II or III-mix as follows: 
Superscript II-Mix 
 x1 x12 x14 x16 
5x buffer 2 l 24 l 28 l 32 l 
0,1M DTT 1 l 12 l 14 l 16 l 
10mM dNTPs 0,5 l 6 l 7 l 8 l 
DPEC H2O 1,25 l 15 l 17,5 l 20 l 
Superscript II (rev. 
transcriptase) 
0,25 l 3 l 3,5 l 4 l 
RNAase inhibitor 0.5 l < 3 l < 3 l < 3 l 
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After 3 min running at 95°C, if the temp. in PCR machine has reached to 50°C, then  
Add 5l Superscript mix into RNA-Primer-mix ad then mix it well. Incubate further 
at 50°C for 90 min and let it run till it’s gone through. Newly produced cDNA was 
either used for loading on 6% sequencing gel or was stored at -20°C. 
 
2.9.13.7 8% sequencing gel  
Following components of 8% sequencing gel was mixed properly and poured in 
between the sequencing gel plates followed by placing 16 well combs. After adding 
TEMED in the gel mixture, it is essential to pour the gel as soon as possible otherwise 
it can solidify before pouring into the gel plates. 
23.3 ml sequencing gel Verdünner (Roth) 
12.7 ml sequencing gel concentrate (Roth) 
4 ml sequencing gel-buffer (Roth)  
500 l 6% APS (Ammonium persulfate) 
40 l TEMED 
The polymerized gel was prewarmed up to 50˚C before loading the samples for the 
best result. The voltage was supplied up to maximum but current was maintained up 
to 40W. When the gel temperature was reached up to 50˚C the 5 l STOP-Solution 
was added to each sample (cDNA) and incubated at 95°C for 3 min (in PCR 
machine). 20 l of each samples were loaded into the wells. Labeled marker (10 l 
was also loaded for the size control. Gel was run at 1500 volt and 25W till the dark 
blue dye reaches the end of the gel and the approximate time required was 2 h. 
When gel run was over then the glass plate was separated very carefully and the gel 
was placed on wattman-paper (right size) and was wrapped with plastic foil (plastic 
foil side at the top. Care is always exercised during the whole experiment because of 
radioactive hazardous material 32P. The wrapped gel was dried in vacuum drier for 
90-120 min. When the gel was dried then it was placed onto the screen cassettes and 
make sure that gel side facing towards the white side of screen platter and incubated 
over night or as desired at room temperature. Next day the gel was scanned on the 
typhoon and the band was quantified using GenQuant software.  
 
 
2.9.14 Chloramphenicol Acetyl Transferase (CAT Assay)  
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Aim of the CAT assay is to analyze the effect of Verapamil on CAT protein 
expression of the plasmid containing CAT gene (pPOL1-CAT-RT) in the presence of 
4 other helper plasmids pHMG-PB1, pHMG-PB2, pHMG-PA, and pHMG-NP 
derived from PR8 virus system that supports CAT gene expression. CAT assay was 
performed to check the acetylating activity of CAT protein expressed in 293T cells.  
Confluent 293T cells were distributed in 3.5 cm dishes and incubated overnight at 
37
0
C in CO2 incubator. Next day confluent (80-90%) cells were transfected with 7 μg 
plasmid DNA (2:1:1:1:2 ratio of pPOL1-CAT-RT, pHMG-PB1, pHMG-PB2, pHMG-
PA and pHMG-NP plasmid respectively of the stock 1g/l) using lipofectamine and 
plus reagent.  Between 6-8 h.p.t media was changed with complete media or only 
1xDMEM with P/S (without FCS) and incubated overnight or until 48 h at 37
0
C in 
CO2 incubator. 
In the same way of transfection method for pPOL1-CAT-RT along with pHMG-PB1, 
pHMG-PB2, pHMG-PA and pHMG-NP, 293 T cells were also transfected with 
plasmid containing GFP gene described as pPOL1-GFP-RT along with pHMG-PB1, 
pHMG-PB2, pHMG-PA and pHMG-NP used as a positive control to analyze the 
transfection efficiency. After 48 h.p.t pPOL1-GFP-RT transfected cells were analyzed 
microscopically. If the transfection efficiency for GFP control was good then pPOL1-
CAT-RT plasmid transfected cells were either left untreated or treated with Verapamil 
(100 μ) after 48 h.p.t and incubated at 370C with 5% CO2 incubator for further 8 h. 
 
2.9.14.1 Lysis 
48 h.p.t cells were washed with 1x PBS
++
 and cells were scraped in 500l 1x PBS++ 
and transferred in new eppendorf (on ice). Cells were centrifuged at 3000 rpm at 4˚C 
for 1 min. Pellet was resuspended in 100 l of 0.25M Tris (pH-7.5). Resuspended 
pellet was incubated for 2 min in liquid nitrogen followed by 5 min incubation at 
37˚C in water bath. This process was repeated for two times and centrifuged at 3000 
rpm for 1 min at 4˚. 100l supernatant, which is enzyme extract, was transferred in 
new eppendorf on ice and was used for CAT assay or was stored at -70˚C. 
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2.9.14.2 Determination of protein amount 
5 l sample from the cell lysate was taken to measure the protein concentration. 
Briefly, 200 l of Bio-Rad protein assay buffer and 800 l of ddH2O were mixed with 
5 l of sample in a 1.5 ml eppendorf tube. The concentration of protein was calculated 
by   measuring the absorbance at 595 nm in a DU-70 spectrophotometer (Beckman). 
According to the indicated absorbance, the protein concentration of different samples 
could be calculated and compared and equal amounts used for the enzyme assay.  
 
2.9.14.3 Enzyme dilution:  1:10, 1:100, and 1:1000 
Enzyme extract (prediluted equal amounts, see above) was diluted in 1:10, 1:100, and 
1:1000 ratios. 10 l of enzyme extract was diluted in 90 l tris buffer in eppendorf 
that gives 1:10 dilution. From this mixture, 10 l was further diluted in 90 l tris 
buffer in eppendorf that gives 1:100 dilutions. And finally 10 l of this mixture was 
further diluted in 90 l tirs buffer in eppendorf that ends in 1: 1000 dilution of 
enzyme extract. This can be either used for the experiment or can be stored at -20˚C. 
 
2.9.14.4 Chloramphenicol reaction 
50 l of each prediluted enzyme (1:10, 1:100 and 1:1000) extract was incubated with 
20 l (4mM) AcCoA and 5 l BODIPY. It was mixed properly and this 75 l reaction 
mixture was incubated at 37˚C for 2.30 h in a water bath. In the mean time running 
chamber was set up. Running buffer was made by mixing 26 ml methanol and 174 ml 
chloroform (13:87) and poured into the chamber and covered with lid for overnight to 
generate vapours. If the mixture does not dissolve after addition of BODIPY then 1.5 
ml methanol was added.                             
After 2.30 h incubation of reaction mixture, the substrate was extracted by adding 500 
l ethyl acetate to the mixture by vigorously vortexing for 5 min followed by 5 min 
centrifugation at 13000 rpm at room temp. Two phases will be created upper ethyl 
acetate layer (450 l) and lower water layer. Ethyl acetate layer was transferred into 
new eppendorf (with holes made in the lid) and were concentrated in the form of dried 
pellet for 5-20 min in speed vac. 
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2.9.14.5 Loading samples on TLC plate 
Speed vac dried pellet was dissolved in 20 l ethyl acetate and was loaded in the form 
of little dots on TLC plate with the help of air gas supply. Air supply helps 
minimizing spread of ethyl acetate on TLC plate during sample loading. The sample 
loaded TLC plate was placed in pre-equilibrated running buffer in an inclined 
position. As soon as TLC plate touches the buffer, migration of samples starts by 
capillary action and is completed in about 30 min. The presence of acetylated 
chloramphenicol was visualized as a light green color spot on the chromatogram in 
UV-light. The TLC plate was removed from the buffer at the end of 30 min and 
allowed to dry. Later the spots were scanned by typhoon machine and quantified by 
Genuine software. 
 
2.9.15 Verapamil doses preparation for animal experiments 
To investigate the inhibitory effect of Verapamil on virus replication in either of 
infected mouse, ferret or guinea pig, drug dosage can be prepared according to 
pharmaceutical and dispensing law. In animal experiment we prefer to use mouse as a 
model for infection and subsequently drug treatment because certain strain of mouse 
is adapted for influenza virus infection. Verapamil-HCl powder has Molecular weight 
491.6g/l=1M (491.6mg/l=1mM, 49.1mg/l=100μM). In order to achieve the same non 
toxic concentration (100μM) which was used for in vitro studies, the Verapamil doses 
are calculated depending on the body weight or volume of the animal and in this case 
mouse. The body weight of mouse varies from 25 to 35 gm but 30 gm is most likely. 
Verapamil is water soluble. Either non-pyrogenic water for injection or non-pyrogenic 
saline water (water containing 0.8% NaCl) are recommended for diluting Verapamil 
for animal experiment. Normal water is not recommended for diluting Verapamil or 
any drug because it causes fatality and serious illness to the animal. Calculated drug 
dosage could be administered in the mouse by various modes but intraperitoneal 
injection is most preferred. Administration of drug through injection should be 
continued depending on the availability of the drug in the body, metabolic rate of the 
drug in the body or maintaining the continuous supply of constant concentration of 
drug in the body. Above 5 mg/mouse is not recommended. Intra peritoneal (1P) 
injection is recommended in most of the cases but other routes of drug administration 
can be also used. 
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Formulae of pharmaceutical doses calculation: Drug doses for humans are 
calculated by this formula:  
70kg (human weight)   = 50, Where x is the human dose. 
                                     200gm rat weight        x 
 
 
 
Verapamil Acute Toxic Doses (LD50) 
Mouse: 
i.v 7.6mg/kg    (Windholz1983) 
s.c 68mg/kg    (Windholz1983) 
i.p   68mg/kg   (Windholz1983) 
p.o 114mg/kg  (Windholz1983) 
Rat: 
i.v    16mg/kg   (Windholz1983) 
s.c 107 mg/kg (Windholz1983) 
i.p    68mg/kg  (Windholz1983) 
p.o  114mg/kg (Windholz1983) 
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3. Results 
3.1 Analysis of the role of tyrosine kinase activity in influenza virus infected cells 
Previous studies (254), demonstrate that Raf/MEK/ERK (MAPK)-cascade is an 
essential host function for efficient influenza virus replication. Using MEK inhibitor 
(U0126) at non toxic concentration resulted into the blocked of RNP-export from 
nucleus to the cytoplasm leading to reduced virus titers. To demonstrate that the 
influenza virus induced Ras-activation could be an upstream kinase for the 
transmission of signals to the Raf/MEK/ERK (MAPK) cascade. Ras is a GTP-binding 
protein that can be activated by a number of external stimuli including viruses. The 
activation of Ras can lead to activation of the MAP kinase signalling pathway. I 
wanted to analyze the phosphorylation of tyrosine residues in virus infected MDCK 
cells. Therefore I infected MDCK cells with IV (MOI=1). At indicated time points 
cells were fixed permeabilized and stained with primary mouse anti-NP (green) and  
mouse anti-phosphor tyrosine specific antibodies (red) followed by FITC conjugated 
anti-mouse and Texas red conjugated anti-mouse secondary antibodies. The confocal 
laser scanning microscope result shows that receptor tyrosine kinase activity (which 
could activate MAPK via Ras) is not significantly elevated in virus infected cells. 
This indicates that therefore PKCs might also play a role.  
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Fig 3.1: Confocal laser scanning microscopic analysis of tyrosine 
activity in Influenza virus (IV) infected cells: MDCK cells were 
infected with IV (MOI=1). At indicated time points cells were fixed 
permeabilized and stained with primary mouse anti-NP (green) and 
mouse anti-phosphor tyrosine specific antibodies (red) followed by FITC 
conjugated anti-mouse and texas red conjugated anti-mouse secondary 
antibodies.  
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3.2 Analysis of the importance of PKC-activity versus Ras-activity in influenza 
virus infected cells. 
It was also not determined yet that, what could be the upstream kinases for activating 
Raf/MEK/ERK signalling. There are two possible upstream kinases PKC or Ras 
which could be involved in the virus induced MAPK activation. Previous studies 
(262), suggests that PKC and or  are activated when human polymorphonuclear 
leukocytes were incubated with influenza virus. PKCII isoform is activated in early 
influenza viral replication but not PKC (263). On the basis of above mentioned 
literature, I wanted to compare the importance of PKC or Ras on virus replication by 
analyzing virus titers. Therefore MDCK cells were transfected with plasmids 
expressing either dominant negative (DN-PKC) or (DN-Ras) which reduces 
signalling via PKC or Ras. 24 h p.t cells were infected with IV (MOI=1) and at 
indicated time points (6 and 8 h.p.i.) supernatant were collected and virus titer was 
determined. My comparative analysis shows that PKC is more important for virus 
replication, while Ras play
’
s a minor role in virus replication. These data argue 
against an important role of Ras for MAPK- activation in IV infected cells (265).  
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3.3 Analysis of the cell viability (+/-) Verapamil treatment 
In order to assure that Verapamil (which is a calcium channel blocker and indirect 
inhibitor of PKC) has no detrimental effect on cell survival at concentration 
(100μ) used in the experiments I investigated the cell viability by the MTT-
Formazan test. This assay measures the activity of mitochondrial dehydrogenase in 
the living cells. 3-(4, 5-dimethylthiazole-2-yl)-2, 5-diphenyl tetrazolium bromide 
(MTT) is taken up by the cells and reacts with NADH, which is reduced to NAD. This 
reaction produces blue formazan crystals in living cells. The MTT assay shows that 
Verapamil has no significant toxic effect on cell survival.  
 
 
 
 
Vector DN PKC 
 6h  8h 
DN PKC Vector DN Ras DN Ras 
Fig 3.2: Comparative study of virus titration from the supernatants of FPV 
infected cells expressing Dn-PKC or Dn-Ras (n=3):  MDCK cells were 
transfected with plasmids expressing either DN-PKC or DN-Ras. 24 h p.t cells 
were infected with IV (MOI=1) and at indicated time points (6 and 8 h.p.i.) 
supernatant were collected and virus titer was determined.  
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3.4 Analysis of IV titers from infected A549 cells (+/-) Verapamil treatment  
Literature shows that PKC-inhibitors reduce influenza virus entry if added early in 
infection. Also other mentioned literature suggests that Ca
++
 influx is increase in IV 
infected cells and PKC is a calcium dependent kinase therefore I wanted to 
investigate the effect of Verapamil on virus replication by analyzing virus titers. 
Therefore A549 cells were infected with IV (MOI=5) and 2 h.p.i. cells were either left 
untreated or treated with Verapamil at non toxic concentration (100M). At indicated 
time points virus supernatants were collected and virus titration was performed. The 
result shows that Verapamil leads to strong reduction in virus titers, which suggests 
that Verapamil is a potent inhibitor of virus replication. Therefore Verapamil can be 
used as antiviral therapeutic intervention against influenza. Verapamil is an already 
marketed and licensed drug for the treatment of the cardiovascular diseases like, heart  
 
 
Fig 3.3: Analysis of the effect of Verapamil on cell survival or cell viability test 
(MTT) (4): A549 cells were treated with non-toxic concentration of Verapamil 
(100M/ml) for different time points. MTT assay was performed.  
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attack, high blood pressure, angina etc. Hence this drug could be interesting in the 
direction of antiviral approach. 
 
 
3.5 & 3.6 Analysis of the effect of Verapamil on cellular protein production and 
on host cell shut-off mechanism respectively 
Since Verapamil is a potent inhibitor of IV replication and might be used as antiviral 
drug. In order to make sure that Verapamil does not interfere with cellular protein 
production.  I wanted to investigate the total protein amount in cells either left 
untreated or treated with Verapamil. Equal amount of A549 cells were seeded. After 
confluency cells were either left untreated or treated with Verapamil at non toxic 
concentration (100μ). At indicated time points cell lysates were made. 
Spectrophotometric analysis of each sample at 595 nm wavelength shows that there is 
no significant variation in the total amount of protein, which suggests that Verapamil 
does not inhibit cellular protein production (translation). 
In virus infected cells ERK2 protein production seems to be reduced at late time 
points (8-10 h) due to host cell shut-off mechanism. Verapamil treatment seems to 
reduce this effect. 
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Fig 3.4: Plaque titration analysis of the inhibitory effect of Verapamil on 
virus replication (n=4): A549 cells were infected with IV (MOI=5) and 2 h.p.i. 
cells were either left untreated or treated with Verapamil at non toxic 
concentration (100M). At indicated time points virus supernatants were 
collected and virus titration was performed.  
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Fig 3.5: Spectrophotometric analysis of the effect of Verapamil on 
cellular protein production (n=4): Equal amount of A549 cells were 
seeded in 3.5 cm dishes. After confluency cells were treated with 
Verapamil at non toxic concentration (100μ). At indicated time points 
cell lysates were made. Spectrophotometrically O.D of each samples were 
measured. 
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3.7 Analysis of the PKC-and ERK-activation in virus infected A549 (+/-) 
Verapamil 
As mentioned in the literature that Raf/MEK/ERK (MAPK)-cascade is essential host 
function required for virus for its efficient replication and this cascade is activated at 
late time replication cycle. (254) indicates that IV infection leads to strong ERK-
activation and MEK inhibitor (U0126) strongly reduces ERK-activation. In order to 
establish the connection between PKC and ERK-activation (phosphorylation), I 
wanted to investigate the effect of Verapamil on virus induced Raf/MEK/ERK 
induction. Therefore A549-cells were infected with IV (MOI=1) and either left 
untreated or were treated with Verapamil (100M/ml, 2 h p. i.), cell lysates were 
made at 8 h p.i and 10h p. i. and used for western blot-analysis using phosphor-
specific mAbs. Loading was controlled using anti PKC and ERK-specific mAbs. 
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Fig 3.6: Western blot analysis of the effect of Verapamil on ERK2 protein 
production in IV infected A549 cells (n=3): A549 cells were infected with 
IV and either left untreated or treated with Verapamil at non toxic 
concentration (100μ). At indiacted time point’s, cell lysates were made and 
analzed for ERK2 protein production.  
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The effect of Verapamil on virus-induced ERK-activation indicates that signal to the 
Raf/MEK/ERK (MAPK)-cascade is dependent on PKC-activation.  
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Fig 3.7: Western blot analysis of the PKC- & ERK-activation (n=3): A549-cells were 
infected with IV (MOI=1) and either left untreated or were treated with Verapamil 
(100M/ml, 2 h p. i.), cell lysates were made at 8 h p.i and 10h p. i. and used for WB-
analysis using phosphor-specific mAbs. Loading was controlled using anti PKC and 
ERK-specific mAbs.  
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3.8 Analysis of the PKC-and ERK-activity in virus infected A549 (+/-) 
Verapamil 
The previous result shown in the above experiment suggests that ERK is activated via 
PKC signalling. The negative effect of Verapamil was strong on ERK-activation 
(phosphorylation) while the effect was weak on PKC-activation (phosphorylation). 
Therefore the idea came that Verapamil might not block the activation of PKC but 
PKC-activity might be blocked. Hence I wanted to investigate the activity of PKC 
and ERK using MBP as a substrate by immune complex kinase assay (ICA). A549-
cells were infected with IV (MOI=1) and either left untreated or were treated with 
Verapamil (100M/ml, 2h p.i.), cell lysates were made at 8 h p.i and 10 h p.i. and 
used for ICA, to analyze PKC- and ERK kinase-activity respectively. Loading was 
controlled with anti PKC and ERK-specific mAbs in WB-analysis. The result shows 
that Verapamil strongly reduces ERK activity and to a minor extent PKC-activity. 
This indicates that virus induced Raf/MEK/ERK-signal transmission is dependent on 
PKC-activity. (This work was performed in collaboration of Prof. Dr. Stephan 
Ludwig, University of Munster, Germany). 
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Fig 3.8: Immune complex assay (ICA) analysis of PKC- & ERK-activity (n=2): 
A549-cells were infected with IV (MOI=1) and either left untreated or were treated with 
Verapamil (100M/ml, 2h p.i.), cell lysates were made at 8 h p.i and 10 h p.i. and used for 
ICA, using myelin basic protein (MBP) as substrate indicating PKC- and ERK kinase-
activity respectively. Loading was controlled with anti PKC and ERK-specific mAbs in 
WB-analysis.   
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3.9 Analysis of the intracellular localization of pPKC in TPA activated A549 
cells (Control experiment) 
In normal state PKC is cytoplasmic. Literatures also suggest that TPA induced  PKC 
- is translocated to the plasma membrane. This experiment was used as positive 
control to demonstrate virus induced PKC localization in virus infected cells. The 
confocal result indicates that TPA induced phosphorylated PKC (pPKC) is 
localized into plasma membrane from the cytoplasm.  
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Fig 3.9 : Confocal laser scanning microscopic analysis of 
intracellular localization of phosphorylated PKC: A549 cells were 
stimulated by TPA (200ng/ml). At indicated time points post treatment 
cells were fixed and stained with primary goat anti-pPKC and mouse 
anti-NPC. Cells were then washed and incubated with secondary FITC 
conjugated anti-goat and texas red conjugated anti-mouse antibodies. The 
result indicates that TPA induced phosphorylated PKC (pPKC) is 
localized into plasma membrane from the cytoplasm. Nuclear pore 
complex (NPC) to visualize the nucleus is detected by using mouse anti-
NPC antibodies (red). 
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3.10, 11 & 12 Analysis of the RNP-export in virus infected A549 cells (+/-) 
Verapamil treatment 
I have shown in my previous result, that Verapamil strongly reduces virus titers. 
Literature indicates that RNPs of influenza virus are essentially exported out from 
nucleus to the cytoplasm for the production of new infectious progeny virus. The 
inhibitory effect of Verapamil on virus replication raised interesting question 
regarding PKC-activation and RNP-export. Therefore I wanted to investigate the 
PKC-activation and RNP-export in untreated and treated cells. To this point A549 
cells were infected with IV (MOI=1). 2 h.p.i cells were either left untreated or treated 
with Verapamil. At indicated time point’s p.i, cells were fixed permeabilized and 
stained with primary mouse anti-NP and goat anti-pPKC antibodies followed by 
secondary FITC conjugated anti-mouse and CY5 conjugated anti-goat antibodies. 
Confocal laser scanning microscope result shows that late in the virus replication 
cycle (8-10 h), PKC is activated at a time point when RNPs are exported out from 
nucleus to the cytoplasm. That suggests that RNP-export is connected to PKC 
activation and that PKC-activation and RNP-export are strongly blocked by 
Verapamil leading to inefficient virus replication. 
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Fig 3.10: Confocal laser scanning microscopic analaysis of the RNP-export and 
activation of PKC (pPKC) in IV (MOI=1) infected A549-cells: A549 cells were 
infected with IV (MOI=1). At indicated time point’s p.i cells were fixed permeabilized 
and stained with primary mouse anti-NP and goat anti-pPKC antibodies followed by 
secondary FITC conjugated anti-mouse and CY5 conjugated anti-goat antibodies.  
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Fig 3.11: Confocal laser scanning microscopic analysis of the effect of 
Verapamil on RNP-export: A549 cells were infected with IV (MOI=1) and after 2 
h p.i cells were treated with Verapamil at non toxic concentration (100μ). At 
indicated time point’s p.i cells were fixed permeabilized and stained with primary 
mouse anti-NP and goat anti-pPKC antibodies followed by secondary FITC 
conjugated anti-mouse and CY5 conjugated anti-goat antibodies.  
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Fig 3.12: Confocal laser scanning microscopic analysis of 
PKC- activation in IV infected MDCK cells: MDCK cells were 
infected with IV (MOI=1). 2 h p.i cells were either left untreated or 
treated with Verapamil at non toxic concentration (100μ). At 
indicated time point’s cells were fixed, permeabilization and stained 
with primary mouse anti-NP antibodies and goat anti-pPKC 
antibodies followed by secondary FITC conjugated anti-mouse and 
Cy5 conjugated anti-goat antibodies. (265) 
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3.13.1& 3.13.2 (A-D) Analysis of viral protein production in virus infected A549 
cells (+/-) Verapamil treatment 
In the first experiment I analyzed the inhibitory effect of Verapamil on PKC 
mediated Raf/MEK/ERK signalling, RNP-export and virus replication. In addition to 
this effect, analysis of additional inhibitory effect of Verapamil on viral protein 
production was an interesting question for me. Therefore I wanted to investigate the 
effect of Verapamil on different viral proteins (PB1, NP, M1 and NS1) production 
level. A549 cells were infected with IV at (MOI=1) and 2 h.p.i cells were treated with 
Verapamil at non-toxic concentration (100μ). After indicated time points p.i and 
treatment, cell lysates were made and were used for western blot for viral protein 
detection. Blots were incubated with primary antibodies (goat anti-PB1-, 1:200; 
mouse anti-NP-, 1:200; mouse anti-M1-, 1:500; and goat anti- NS1-1:500) and 
subsequently with HRP-conjugated secondary antibodies. Equal amounts of ERK2 
protein were loaded.  Western blot result shows that Verapamil strongly inhibits the 
amount of viral proteins (PB1, NP, M1 and NS1) production, which suggests that 
Verapamil might also effect viral replication and/or transcription. 
Fig 3.13.1 belongs to one set of experiment where triplicate samples were pooled 
together at indicated time points post infection (+/-) Verapamil and analyzed for the 
detection of viral proteins (PB1, NP and NS1). 
Fig 3.13.2 (A-D) belongs to another set of experiment where also triplicate samples 
were pooled together at indicated time points post infection (+/-) Verapamil and were 
analyzed for viral proteins (PB1, NP, M1 and NS1). 
 Both results (Fig 3.13.1 & Fig 3.13.2 (A-D) indicate that Verapamil strongly reduces 
viral protein production that might be one of the potent causal factor for the inhibition 
of virus replication.  
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Fig 3.13.1: Western blot analysis of the inhibitory effect of Verapamil on viral 
protein production: A549 cells were seeded in 3.5 cm dishes and were infected with 
IV at (MOI=1) and 2 h.p.i cells were treated with Verapamil at non-toxic 
concentration (100μ). After indicated time points cell lysates were made and were 
used for viral protein detection. Blots were incubated with primary antibodies (anti-
goat PB1-, 1:500; anti-mouse NP-, 1:500; and anti-goat NS1-1: 500) and subsequently 
with HRP-conjugated secondary antibodies. Equal amounts of protein were loaded 
(ERK2).  
6 
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Fig 3.13.2 (A) Production of PB1 protein of influenza virus. 
Fig 3.13.2 (B) Production of NP protein of influenza virus. 
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Fig 3.13.2 (C) Production of M1 protein of influenza virus. (DAB/Urea staining) 
Fig: 3.13.2 (D) Production of NS1 protein of influenza virus. 
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3.14 (A & B) Primer extension analysis of the effect of Verapamil on viral mRNA 
production 
The above result of the analysis of the effect of Verapamil on viral protein production 
provided the formal proof that inhibition of viral protein production by Verapamil 
could be due to the impairment of viral replication and/or transcription. The above 
result also shows that Verapamil strongly inhibits PB1 protein which is one of the 
subunits of the viral polymerase. Therefore I wanted to analyze the effect of 
Verapamil on viral polymerase activity by quantifying different RNA (cRNA, vRNA 
and mRNA) species production using Primer Extension Assay. 
 293T cells were seeded in 3.5 cm dishes and were either transfected with 5 plasmids 
for the expression of the viral polymerase subunits, the NP and a virus-like vRNA 
(pHMG-PB1, -PB2, -PA, -NP, and pPOL1-CAT-RT) (1, 2) or with the pPOL1-CAT-
RT plasmid alone and then super infected with IV (MOI=1) 24h p.t. (3, 4). 32 h p.t. 
(1, 2) or 8 h p.i. (3, 4) total RNA was isolated and used for primer extension analysis. 
The relative amount of virus-like mRNA normalized to a loading control (5SrRNA) 
was calculated. Result indicates that Verapamil seems to have a negative effect on 
viral mRNA production in virus infected cells, while it seems not to effect mRNA 
production in a plasmid based replication system. This indicates that the effect of 
Verapamil on viral transcription depends on virus infection. 
Fig 3.14 (B) shows the original 8% sequencing gel picture for the quantification of 
mRNA production. Fig 3.14 (A) is the derivatives of Fig 3.14 (B) 
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Fig 3.14 (A): Primer extension analysis of the effect of Verapamil on viral 
polymerase activity (n=2): 293T cells were seeded in 3.5 cm dishes and were either 
transfected with 5 plasmids for the expression of the viral polymerase subunits, the 
NP and a virus-like vRNA (pHMG-PB1, -PB2, -PA, -NP, pPOL1-CAT-RT) (1, 2) or 
with the pPOL1-CAT-RT plasmid alone and then super infected with IV (MOI=1) 
24h p.t. (3, 4). 32 h p.t. (1, 2) or 8 h p.i. (3, 4) total RNA was isolated and used for 
primer extension analysis. The relative amount of virus-like mRNA normalized to a 
loading control (5SrRNA) was calculated.  
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Fig 3.14 (B): 8% sequencing gel picture of the primer extension analysis of 
the effect of Verapamil on viral mRNA production. 
5 μl trizole isolated RNA was used for making cDNA. cDNA was further used 
for primer extension with the primer designed for the amplification of the 
product length of the viral mRNA which is about 106 nuclotide in length. I 
also used 5SrRNA as a loading control for the respective samples to be sure 
that the samples were loaded equally. Lower intense signals are radioactive 
labeled primers which did not bind with the target sequence. H20 was also 
used as a negative control where we see no amplification.  
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3.15 Analysis of the expression of CAT-protein by transfecting 293T cells with 
pPOL1-CAT-RT along with four helper plasmids (pHMG-PB1, pHMG-PB2, 
pHMG-PA and pHMG-NP) 
pPOL1-CAT-RT plasmid transfection leads to the synthesis of the viral RNA like 
transcript and it is under the control of cellular promoter. The newly synthesized 
vRNA like transcript is dependent on the viral polymerase for its transcription and 
replication leading to the expression of CAT-protein. To demonstrate the effect of 
Verapamil on viral polymerase that might lead to reduced expression of CAT-protein, 
therefore I was interested to perform CAT-assay. This experiment is just a positive 
control experiment for the further analysis of the effect of Verapamil on viral 
polymerase activity by analyzing CAT-protein expression either in Verapamil treated 
or untreated samples. 
My preliminary result shows that chloramphenicol is acetylated by CAT enzyme that 
suggests that CAT-enzyme expression is efficient for minireplicon system. On the 
basis of this result further analysis of the effect of Verapamil on CAT-protein 
expression, could be exercised. Unacytylated form of chloramphenicol was observed 
in the maximum dilution (10
-3
) of the extracted enzyme that suggests that acetylation 
of chloramphenicol is inversely proportional to the dilution factor.  
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Fig: 3.15 Chloramphenicol acetyl transferase analysis of the 
CAT protein expression: 293T cells were transfected with 
pPOL1-CAT-RT. After 48 h p.t. cell lysates were made and used 
for CAT assay. Enzyme extracts were diluted as 10
-1
, 10
-2
, and 10
-3
. 
The reaction mixture was placed on TLC sheet and lowered into the 
TLC chamber with solvent in the bottom. Spotted reaction mixture 
on TLC plate was allowed to migrate up the TLC sheet. When the 
solvent reaches the top of the TLC sheet, it was stopped and 
allowed to dry. Later it was to be quantified by typhoon but I have 
not quantified the visible spots on the sheet. The amount of 
acetylation is directly proportional to the amount of CAT enzyme 
present.  
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Discussion  
Influenza A and B viruses are important worldwide pathogens
 
for humans and 
animals and cause devastating epidemic and pandemic
 
outbreaks and is considered as 
an annual major public health threat. With the realization that future pandemic of 
influenza in humans is inevitable and perhaps imminent. One must look at the 
therapeutic intervention of antiviral agents against influenza. 
 
Previous studies (254) have revealed that both influenza A and B viruses activate
 
the 
cellular Raf/MEK/ERK (MAPK)-signalling cascade. The virus-induced MAPK 
signalling is activated late in the viral
 
replication cycle, and RNP nuclear export is 
dependent on this
 
cellular function and block of this
 
signalling pathway using MEK 
inhibitors (U0126) at non toxic concentration strongly reduces ERK-activation, RNP-
export and virus titers thereby leading to inefficient virus replication without the 
emergence of resistant variants (266). 
 
However additional information was needed in order to understand the mechanism of 
MAPK-signalling and for subsequently targeting the virus induced signalling pathway 
as an anti-viral approach. 
 
MAPK cascades
 
are key regulators of cellular responses such as proliferation,
 
differentiation, and apoptosis. The Raf/MEK/ERK
 
cascade is the prototype of MAPK 
cascades. Growth factor-induced
 
signals are transmitted by consecutive 
phosphorylation from
 
the kinase Raf via MEK to ERK, which translocates to the 
nucleus
 
to phosphorylate a variety of substrates. The MAPK-cascade is normally 
activated by membrane proximal events through activation of PKCs or through 
activation of Ras. 
 
The literature mentioned in the introduction part indicates that in virus infected cells 
there is a significant calcium influx and other literature suggest that a calcium channel 
blocker (Verapamil) inhibits virus replication. It means that calcium is somehow 
playing a role in virus induced signalling pathway.  As classical PKCs are dependent 
on calcium therefore the idea came that Verapamil might block calcium influx from 
calcium storage to the cytoplasm to demonstrate the effect of calcium dependent 
PKC on virus induced Raf/MEK/ERK signalling.  
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As discussed in the introduction part PKC and PKC are classical PKCs and they are 
activated by Ca
2+
 and DAG (diacyl glycerol). PKC-inhibitors reduce virus entry if 
added early in infection. PKCII isoform is activated in early influenza viral 
replication but not PKC (263).  
 
These above mentioned data have been the cornerstone for the further investigation of 
the role of calcium induced PKCs in influenza virus infection and of PKC as a 
particular factor of interest for virus-induced Raf/MEK/ERK-signalling, but not of 
PKCII because it was shown to be involved during virus entry. 
 
As I introduced in the beginning of this discussion part the inhibitory effect of the 
MEK inhibitor (U0126) on virus replication, which became one of interesting piece of 
research to me to further investigate, the upstream cellular factors to be involved in 
the mechanism of signal transmission to the MAPK-cascade in virus infected cells. 
Since it was not determined yet that, what could be the upstream kinases for 
activating Raf/MEK/ERK signalling therefore data from (252) was further elaborated 
by me to investigate the role of PKC as a cellular factor which could be responsible 
for MAPK-cascade activation. There are two possible upstream kinases either PKC 
or Ras, which could be involved in the virus induced MAPK activation. Therefore I 
used Verapamil which is an indirect inhibitor of PKC to analyze its effect on PKC 
mediated Raf/MEK/ERK signalling as well as on viral factors (viral proteins and viral 
polymerase). 
  
In context to the importance of Ras involvement in virus replication, my first 
experiment was to investigate the phosphorylation status of tyrosine residues in virus 
infected cells as Ras is being activated by tyrosine kinases. This could mean that 
receptor tyrosine kinase in virus infected cells could lead to the phosphorylation of the 
tyrosine residues of Ras and to its activation. Confocal laser scanning microscope 
result (shown in the fig 3.1) demonstrates that the tyrosine phosphorylations in virus 
infected cells are weak suggesting that Ras-activity is involved in virus replication to 
a minor extent. 
 
Therefore I was interested to demonstrate in a comparative analysis of the importance 
of PKC versus Ras. To this point I investigated the virus titers from infected cells 
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either expressing dominant negative PKC or Ras. The titer result (shown in the fig 
3.2) indicates that PKC seems to be more important for virus replication than Ras, 
nevertheless Ras also plays a role in virus replication but to a minor extent. This result 
supports the concept that PKC-activity is important in virus replication. I would also 
like to critically discuss here that within the two hours interval (6-8 hours) the virus 
titers result is slightly increased. That indicates that the effect of dominant negative 
PKC or Ras is not able to block signalling completely. The fact that cellular PKC 
and Ras are also expressed which supports the data of a slight increase of the virus 
titers within the two hours interval. 
 
Ongoing data interested me for further analysis of the effect of calcium channel 
blocker Verapamil on virus replication. As I mentioned in the introduction part that, 
virus infection leads to calcium influx and PKC which is a calcium dependent kinase 
might play a role in the activation of Raf/MEK/ERK signalling cascade, which is a 
prerequisite for virus replication. Therefore I infected the cells and two hours post 
infection I treated the cells with Verapamil, and at indicated time points virus 
supernatant was collected and analyzed for virus titration. The result (shown in the 
fig 3.4) shows that Verapamil strongly inhibits virus replication supporting the idea 
that PKC induced Raf/MEK/ERK signalling is a prerequisite for virus propagation. 
Here I would like to mention that I treated the cells with Verapamil after two hours 
post infection to avoid any effect of Verapamil on virus entry. If Verapamil treatment 
was done at the time of infection virus entry into the cells might be affected, as it was 
shown that PKCII is important for virus entry. My aim was to analyze the effect of 
Verapamil on the late phase of virus replication, when the MAPK-cascade is 
activated.  
  
Since Verapamil strongly reduces the virus titers in virus infected cells therefore the 
interesting question for me was to demonstrate that, Verapamil has no detrimental 
toxic effect on cell survival. Otherwise that could also be one of the genuine reason to 
get reduced virus titers, as there are not enough cells available for virus replication if 
Verapamil kills the cells. Therefore I performed MTT-Formazan test to demonstrate 
the possible negative effect of Verapamil on cell survival and the result (shown in the 
fig 3.3) shows that Verapamil seems to have no significant toxic effect on cell 
survival. That means that, the reduced virus titer was not due to killing of the cells by 
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Verapamil but it was due to the effect of Verapamil on virus replication by yet 
unknown mechanism. 
 
It is also necessary to discuss here that influenza virus one replication cycle takes 
about 10 hours so the effect of Verapamil could be studied either for one replication 
cycle or for multiple replication cycles but at very low multiplication of infeccity 
(about 0.01 or depends on the aim of the experiments). I have also observed that 
infecting cells with higher MOI leads to cell death in very short time if cells are 
incubated for longer time or for multiple replication cycles. Therefore analysis of the 
effect could be studied either for single replication cycle or multiple cycles but at low 
MOI. I have observed that Verapamil strongly reduces the virus titers without killing 
the cells in both of the above cases. 
 
Inhibiting virus replication by Verapamil was a great interest in me to broaden my 
knowledge by acquiring much information about Verapamil and further analysis of 
Verapamil action on cellular and viral factors. In order to assure that Verapamil does 
not inhibit cellular protein synthesis (translation) if Verapamil might be considered as 
an antiviral drug against influenza, therefore I further investigated the effect of 
Verapamil on host protein production, which could also be effected by Verapamil and 
could be one of the potent causal factors for the reduced virus titers. The analysis of 
the effect of Verapamil on cellular protein production (shown in the fig 3.5 and 3.6) 
indicates that Verapamil seems not to effect cellular protein production. This shows 
the exclusive inhibitory potency of Verapamil on virus replication. Hence Verapamil 
could be a potent inhibitor of influenza and might be used as antiviral drug.  I would 
like to mention here that influenza virus replication leads to host cell shut-off (shown 
in the fig 3.6 at 8-10 h p.i) which mean that host protein synthesis (ERK2) is 
impaired at late time point replication cycle of influenza virus and Verapamil seems 
to reduce this effect. 
 
From the above study I got considerable information, that Verapamil strongly reduces 
virus titers suggesting that virus-induced Raf/MEK/ERK signalling is somehow 
effected. Therefore I investigated the connection between virus-induced calcium 
dependent PKC and Raf/MEK/ERK-activation. Therefore, I infected the cells and 2 
h p.i. cells were either left untreated or were treated with Verapamil and lysates were 
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used for western blot to detect the pPKC and pERK-activation. The result (shown in 
the fig 3.7) so far indicates that in late time point post infection (8-10 h), PKC and 
ERK are activated and that Verapamil strongly reduces the activation of ERK. This 
suggests that virus-induced calcium dependent PKC transmits the signals to the 
Raf/MEK/ERK-cascade. Surprisingly the activation of PKC was not blocked by 
Verapamil, which suggests that Verapamil might not inhibit activation of PKC but 
inhibits its activity. Therefore I further investigated the activity of PKC and ERK 
(shown in the fig 3.8) by Immune complex kinase assay (ICA) in cooperation with 
the lab of S. Ludwig, Munster, using MBP as a substrate for PKC and ERK-activity. 
The result of ICA suggests that PKC induced ERK-activity is significantly reduced 
in Verapamil treated cells while the effect of Verapamil was minor on PKC-activity. 
That suggests that virus-induced calcium dependent PKC-activity leads to the 
activation of ERK. 
 
In attempt to broaden my knowledge, a strategy for analyzing the PKC-activation 
and RNP-export in virus infected and either in untreated or Verapamil treated cells 
laser scanning confocal microscope was used. The confocal microscopic result 
(shown in the fig 3.10, 11 and 12) shows that at late time points (8-10 h p.i.) of virus 
replication, PKC is activated when RNPs of influenza virus was exported out from 
nucleus to cytoplasm in untreated cells. In contrast to this, PKC activation and RNP-
export was strongly blocked in Verapamil treated cells. That suggests that RNP-
export, hence efficient virus replication is dependent on virus induced PKC-
activation. In the introduction part I mentioned that Raf/MEK/ERK is an essential 
host function for the efficient virus replication, which is activated at late time point 
post infection and is prerequisite for RNP-export. Therefore confocal or 
Immunoflorescence results supports the idea that virus induced calcium dependent 
PKC-activation transmits the signals to the Raf/MEK/ERK (MAPK)-cascade which 
leads to the RNP-export for the efficient virus replication. 
 
The above analysis have consistently demonstrated and given significant information 
of the negative role of Verapamil on PKC. For a further understanding of the mode 
of action of Verapamil, I further analyzed the possible adverse effects of Verapamil 
on viral factors like viral protein production and viral polymerase function. At this 
point, I investigated the production of viral proteins in cells that were infected and 
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either left untreated or treated with Verapamil. The western blot results (shown in the 
fig 3.13.1 & 3.13.2(A-D) shows that at an early time point (4 h.p.i.) the amount of 
viral proteins (PB1, NP, M1 and NS1) was very low but production levels increased at 
late time point of virus replication (8-10 h p.i.) in untreated cells. In contrast to this, 
viral protein production was strongly inhibited in Verapamil treated cells throughout 
the time course virus replication. This suggests that Verapamil also targets viral 
protein expression. Therefore reduced viral protein production could be another 
genuine possible reason for inefficient virus replication. 
 
PB1 protein of influenza virus is subunit of the viral polymerase. Interestingly the 
western blot analysis shows that, PB1 protein production was strongly reduced in 
virus infected and Verapamil treated cells. This could mean that the viral polymerase 
function might be negatively affected in Verapamil treated cells. Therefore more 
knowledge about the effect of Verapamil on viral polymerase activity was necessary 
to clarify this point. Therefore Primer Extension Assay to determine the production 
level of the different viral RNA species (vRNA, cRNA and mRNA) of influenza virus 
was used. The preliminary result of primer extension (shown in the fig 3.14 (A) and 
(B) 8% sequencing gel picture of primer extension) indicates that Verapamil seems 
to inhibit mRNA production in wild type virus infected cells while it has no 
considerable negative effect on mRNA production in a minireplicon system (plasmid 
based replication system). This suggests that Verapamil negatively effects viral 
transcription in wild type infection. As the approach of determining the effect of 
Verapamil on mRNA production in a minireplicon system has not yet been conclusive 
therefore further research or analysis in this approach is warranted. One possible 
argument against the non inhibitory action of Verapamil on mRNA production in the 
minireplicon system could be that, in the minireplicon system, the viral RNA like 
transcript and the mRNA for the polymerase which are provided by, pPOL1-CAT-
RT, pHMG-PB1, pHMG-PB2, pHMG-PA and pHMG-NP are produced by cellular 
polymerases (POL1 and POL2) and therefore their activity might not be affected by 
Verapamil. Therefore the effect of Verapamil on viral mRNA production in the 
minireplicon system is not considerable. 
  
I further wanted to demonstrate the effect of Verapamil on CAT-protein expression by 
transfecting 293T cells with 5 plasmids (minireplicon system) and my preliminary 
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CAT-assay result (shown in the fig 3.15) without Verapamil treatment shows that 
transfecting 293T cells with 5 plasmids leads to the expression of CAT-protein. This 
experiment was a positive control experiment to show the CAT-protein expression. 
On the basis of above discussion it can be concluded that influenza virus induces 
calcium dependent PKC-activation that transmits the signal to the Raf/MEK/ERK 
(MAPK)-cascade which is a prerequisite host function for the RNP-export from 
nucleus to cytoplasm for the efficient virus replication. And Verapamil which is a 
calcium channel blocker and indirect inhibitor of PKC reduces the PKC transmitted 
Raf/MEK/ERK (MAPK)-cascade activation therefore leading to reduced RNP-export 
and reduced virus titers. Hence Verapamil acts as potent antiviral agent. Besides, 
impairment of MAPK-cascade activation, Verapamil also targets on viral translation 
process thereby reduced viral protein production and impaired RNA-dependent RNA-
polymerase activity of influenza virus. 
 
Taken together, PKC plays an important role in transmitting the influenza virus 
induced signals to the Raf/MEK/ERK-cascade. As PKC-inhibition can be achieved 
at non-toxic Verapamil concentration, leading to strong reduction of virus titers, 
inhibition of this cellular activity might be a potential anti-viral drug against 
influenza.  Verapamil is already used drug in the treatment of cardiovascular diseases 
like, hypertension, high blood pressure, angina etc. with no contra-indications or 
uncommon side effects. Therefore Verapamil could be tested in the treatment of 
influenza.   
Of immediate practical importance is the need to discover potential anti-viral drug in 
response to the next influenza out break, which is a major and serious concern for 
World Health Organization (WHO) and Centre for Disease and Control and 
prevention (CDC). 
  
Influenza is an annual major public health threat. Therefore antiviral agents would be 
one of the therapeutic options to control the wave of epidemic or pandemic influenza 
attack globally until adequate supplies of vaccine are available. Currently two classes 
of antiviral agents are available for the population, the adamantanes (amantadine and 
rimantadine) and the neuraminidase
 
inhibitors (zanamivir and oseltamivir). All of 
these
 
drugs have different efficacies and, are licensed for different
 
age groups. These 
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drugs have certain drawbacks. Viral resistance is often associated with
 
the use of the 
adamantanes and is also found with neuraminidase
 
inhibitors (267, 268).  
Since these influenza antiviral agents are expensive and probably
 
would be in 
relatively short supply, one can consider cellular factors targeted an
 
antiviral 
prophylaxis strategy for treating an infected population.   
 
The possible mass use of influenza antiviral agents raises
 
concern about the 
emergence and spread of drug-resistant influenza
 
viruses. The frequency of resistance 
is
 
much lower for prophylactic than for therapeutic use of these
 
agents. The frequency 
of resistance is lower for
 
the prophylactic use of rimantadine or neuraminidase 
inhibitors
 
than for amantadine. Given that the logistic
 
and theoretical details, cellular 
factor (PKC) targeted use of antiviral agents, Verapamil could be an important 
intervention for epidemic or pandemic influenza. For the potential use of Verapamil 
as anti-influenza drug, our current data (shown by my lab member Dominique 
Brenner) shows that Verapamil treatment does not lead to resistant variants of 
influenza. This suggests that Verapamil could be an interesting and attractive agent 
for scientific study for the therapeutic intervention than the current anti-influenza 
drugs. Verapamil might also reduce the viral load in infected cells while the current 
neuraminidase inhibitors do not reduces the overall viral load in infected cells. 
Taking into consideration as a potential anti-influenza drug, Verapamil should be 
tested in animals and our further ongoing efforts in this direction are under progress. 
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Abbreviations 
AA  amino acids 
AcCoA           acetyl co-enzyme A 
APS  Ammonium persulfate 
AI  Avian influenza 
AIV  Avian influenza virus 
BODIPY         1-acetyl BODIPY-chloramphenicol 
bp  base pairs 
BSA  bovine serum albumin 
BA                  bovine albumin 
o
C  centigrade 
cm  centimeter 
CCB               calcium channel blocker 
CAT  chloramphenicol acetyltransferase 
Ci                    curie 
CMV  cytomegalovirus 
CPSF  cleavage and polyadenylation specificity factor 
cRNA            complementary RNA 
CTP  cytidine triphosphate 
ddH2O deionized distilled water 
DEPC              DiethylenePyrocarbonate 
DMEM Dulbecco's Modified Eagle's medium 
DMSO            Dimethyl sulphoxide 
DNA  deoxyribonucleic acid 
DNase  deoxyribonuclease 
Dn-PKC       dominant negative PKC 
Dn-Ras           dominant negative Ras   
DNTP  deoxynucleoside triphosphate 
DTT  dithiothreitol 
EB                   elution buffer 
ECL                 Enhanced Chemiluminescence 
EDTA  ethylenediamine tetraacetic acid 
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eIF2  eukaryotic translation initiation factor 2 
ELISA             enzyme-linked immunosorbent assay 
ERK  extracellular signal regulated kinase 
et al.  et alii (=and others) 
FCS  fetal calf serum 
FFU                 focus forming unit 
FPV  fowl plague virus 
g  gram 
GFP  green fluorescent protein 
GTP  guanosine triphosphate 
GP  glycoprotein, BDV 
h  hour(s) 
h.p.i                 hours post infection 
h.p.t                 hours post transfection 
HA  hemagglutinin   
HEPES N-2-hydroxyethylpiperazine 
HDV  Hepatitis delta virus  
His  histamine 
HPAIV highly pathogenic avian influenza virus 
HRP                 Horse Radish Peroxidase  
IFA  indirect immunofluoresces assay 
IFN  interferon 
IV                   Influenza Virus 
IAV                 Influenza A virus 
ICA                 Immunocomplex kinase assay 
IFA                 Immunofluorescence assay  
IRF3  IFN regulatory factor 3 
Kb  kilobasepairs 
KDa  kilodalton 
L   RNA-dependent RNA.polymerase, BDV 
LB                   Luria broth 
LPAIV lowly pathogenic avian influenza virus 
M  molar 
M  matrixprotein  
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M1  matrixprotein, Influenza 
M2  ion channel protein, Influenza 
MAPK mitogen-activated protein kinase 
MBP                myelin basic protein 
MEK  MAPK kinase/ERK kinase 
mg  milligram 
min  minute(s) 
ml  milliliter 
mM  millimolar 
mm                 millimeter 
MOI  multiplicity of infection 
mRNA messenger RNA 
MTT              3-(4, 5-dimethylthiazole-2-yl)-2, 5-diphenyl tetrazolium bromide 
n                     number of experiements 
NA  neuraminidase 
NCR  noncoding region(s) 
NEP/NS2 nuclear export factor, non structural protein of Influenza 
NES  nuclear export signal 
NLS  nuclear location signal 
nm                  nano meter 
NP  nucleoprotein 
NPC  nuclear pore complex 
NS1  nonstructural protein 
NEP                nuclear export protein 
ng  nanogram 
nt  nucleotide(s) 
NTP  ribonucleoside triphosphate 
OD  optical density 
P  phosphoprotein, BDV 
P10/x  10 kilo Dalton protein, BDV  
PA  subunit of RDRP, influenza  
PABII  poly (A)-binding protein II 
PAGE  polyacrylamide gel eletrophoresis 
PB1  subunit of RDRP, influenza  
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PB2  subunit of RDRP, influenza  
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PFU  plaque forming unit(s) 
PFA                 paraformaldehyde      
PKC              protein kinase c-alpha 
PKR  dsRNA activated protein kinase 
Pmol  picomolar 
PolyA  polyadenylic acid 
Pol I  RNA polymerase I 
PNK               polynucleotide kinase 
PR8                A/Puerto Rico/8/34 (H1N1)  
PVDF             Polyvinylidene fluoride 
RDRP  RNA-dependent RNA-polymerase 
5S-rRNA        5S-ribosomal RNA 
RNA  ribonucleic acid 
RNase  ribonuclease 
RNasin RNase inhibitor 
RNPs  ribonucleoproteins 
RPA  RNase protection assay 
rpm                revolution per minute 
RT  reverse transcription 
s  second(s) 
SDS  sodium dodecyl sulfate 
TAE                tris-acetate-EDTA 
TE                   tris- EDTA 
TEMED N,N,N',N'-tetramethylethylenediamine 
TLB                tris lysis buffer 
TLC                thin layer chromatography 
TPA                12-O-tetradecanoyl-phorbol-13-acetate (TPA 
Tris  tris-hydroxymethylaminomethane 
ts  temperature sensitive  
Tween 20 polyoxyethylenesorbiten monolaurate 
U  unit(s) 
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U  uridine 
UTP  uridine triphosphate 
UV  ultraviolet 
V  volt 
Vera                Verapamil 
Vol  volume 
vRNA  viral RNA 
cRNA            complementary RNA 
mRNA           messenger RNA   
v/v  volume percentage 
w/v  weight percentage 
WB                  western blot 
g  microgram 
l  microliter 
M  micromolar
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